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Summary 1 
 
I SUMMARY 
 Hsp70 is a highly conserved, ubiquitous molecule and its properties as a 
molecular chaperone are well-described. Additionally, it has been shown to carry out 
important functions in the mammalian immune system. This study addressed several 
open questions concerning the interaction of Hsp70 with the surface of antigen 
presenting cells and the mechanism of Hsp70-mediated cross-presentation. 
 Hsp70 was shown to interact with the surface of antigen presenting cells but 
not with non-immune cells. This binding was dependent on the nucleotide state of the 
chaperone. Only the peptide-loaded, ADP-conformation of the molecule showed the 
described cell-surface interaction, while the empty, ATP-loaded state did not.  
  Previously published receptors for Hsp70 interaction with antigen presenting 
cells were critically evaluated and shown not to play a considerable role in this 
interaction.  
 The specific binding of Hsp70 was shown to be conferred by at least two distict 
interactions, namely by the N-terminal ATPase domain in one case and the C-terminal 
substrate binding domain in the other case.  
 The interaction of Hsp70 with the APCs was shown to lead to cross-
presentation of chaperoned peptide on the cells’ MHC class I molecules. Isolated 
ATPase and substrate binding domain of Hsp70 were analyzed for this function and 
the cross-presentation capabilities were mapped to the substrate binding domain. 
 Additionally, an attempt was made to understand the intracellular pathway of 
the Hsp70/peptide complex, and an assay was developed which allows analysis of the 
contribution of individual compartments employing dominant negative mutants of 
small GTPases. 
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II INTRODUCTION 
II.1 Protein folding and molecular chaperones 
 There is no life imaginable without the various functions that proteins exert. 
Not only do they form the structural basis for all biologic units, but virtually all 
biological processes, from cell growth and division to differentiation and cell death, 
from nutrient uptake to metabolism, are coordinated by highly specialized protein 
networks.  
 In order to acquire their biologic activity, the common feature of all proteins is 
the necessity to obtain their native, functional state – one out of an overwhelming 
number of possible three-dimensional conformations which will render the protein 
biologically active: the protein needs to be folded.  Incorrect folding, or the inability of 
certain proteins to remain correctly folded, results in a wide variety of pathological 
conditions such as Alzheimer’s Disease, Chorea Huntington and cystic fibrosis, to 
name only a few. 
 
II.1.1 Protein folding in vitro and in vivo 
 Since Anfinsen’s pioneering experiments in the 1960’s and 1970’s, it has been 
well known that all information necessary to determine the native structure of a protein 
lies in its primary structure – the amino acid sequence.  (Anfinsen, 1973).  These 
experiments were performed in vitro, where the process of protein folding can be 
followed experimentally by first denaturing, i.e. unfolding a protein, and then allowing 
it to re-fold spontaneously to its native state upon removal or dilution of the denaturing 
agent. 
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 Astonishingly enough, many proteins are able to refold in vitro to their native 
structure, which in almost all cases corresponds to the thermodynamically most 
favorable conformation (Anfinsen, 1973; Dobson and Karplus, 1999). These refolding 
reactions are reversible and proceed with biologically relevant kinetics (Schechter et 
al., 1970). 
 But how do proteins so efficiently and quickly fold into their native state? It has 
been estimated that for a theoretical protein of 150 amino acids, approximately 10300 
possible conformations exist, and it would take about 1011 years to sample all possible 
conformations at maximal rate (Dinner et al., 2000; Levinthal, 1969). This so called 
“Levinthal paradox” led to the conclusion that protein folding cannot occur through 
random, unbiased searching of all possible confirmations (Daggett and Fersht, 2003), 
but rather must be split into individual steps with stabilized folding intermediates.  
 Such experimental setups as have led to our understanding of protein folding 
are usually carried out in a dilute aqueous environment, which reduces unfavorable 
interactions and favors the thermodynamically most stable conformation of a 
polypeptide. The situation in the eukaryotic and prokaryotic cytosol differs strongly 
from the in vitro scenario. As a newly synthesized protein chain emerges from the 
ribosome, it is immediately confronted with multiple influences from the crowded 
cellular milieu. The concentration of macromolecules in the bacterial cytosol has been 
estimated to be as high as 300 mg/ml (Cayley et al., 1991; Zimmerman and Trach, 
1991). 
 The resulting excluded volume effect leads to many non-productive 
interactions of the nascent polypeptide chain with itself as well as with other 
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macromolecules, and such interactions can complete strongly with the folding into the 
native state (Ellis, 2000). 
 Additionally, translation is a relatively slow, vectorial process (4-20 amino 
acids per second), while the rate of folding is much faster (t1/2 < 1 s). As a result, not 
the entire newly synthesized polypeptide chain is available to be folded at once. 
Especially in eukaryotic cells, this leads to an additional complication of the folding 
process due to the prevalence of large, multi-domain proteins, which often need to fold 
cooperatively, with key structures being formed after complete release from the 
ribosome. 
 These complications of protein folding in vivo have been elegantly solved by 
nature through the employment of a whole family of proteins designed to ensure 
correct protein folding and prevent aggregation, as well as to rescue existing proteins 
from partial stress-induced denaturation (Frydman, 2001), the molecular chaperones. 
 
II.1.2 Molecular chaperone systems 
 Molecular chaperones represent several different structural families but share 
common features (Ellis and Hartl, 1999). They do not actively fold their substrates, but 
rather assist the self-assembly of proteins by capturing nonnative structures and 
protecting them from misfolding and aggregation (Hartl and Hayer-Hartl, 2002). Most 
chaperones recognize hydrophobic residues and/or unstructured backbone regions in 
their substrates (Hartl and Hayer-Hartl 2002). Such structural features are typical of  
nonnative proteins and become buried upon correct folding. These functions of 
molecular chaperones are necessary not only to ensure correct folding of newly 
synthesized protein chains, but also during conditions of cellular stress, and many 
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chaperones have been found to be inducible through heat and other stress factors, 
leading to the terminology heat-shock proteins or stress proteins. More than 20 
different families of chaperones are now known, and they are distributed ubiquitously 
in all three kingdoms of life (Agashe and Hartl, 2000). These chaperone families 
cooperate in the cell to build highly functional networks of folding and regulation. 
Figure 1 illustrates the main protein folding pathways in bacteria and eukaryotes. 
  
Figure 1: Model for chaperone-assisted de novo protein folding pathways in eukarya 
and bacteria. 
 
N: Natively folded protein, TF: trigger factor, NAC: nascent chain-associated complex,  
PFD: prefoldin. (A) Bacterial proteins often fold spontaneously upon release from the ribosome and 
ribosome-bound TF. The remainder of proteins are assisted in folding by DnaK/J, which can further 
transfer substrates to the GroEL/ES system. (B) In the eukaryotic cytosol, NAC is thought to interact with 
nascent polypeptide chains, together with Hsp70/40. Some proteins are further transported to the Hsp90 
system, while others are assisted by TRiC, possibly transferred by PFD. Adapted from (Hartl and Hayer-
Hartl, 2002) 
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 The first chaperones to interact with a nascent protein chain in bacterial cells 
are trigger factor and DnaK, the prokaryotic Hsp70 homolog. Trigger factor binds to 
the large ribosomal subunit as well as the nascent protein chain and is thought to 
provide a protective environment that shields hydrophobic stretches to keep them 
soluble. Active folding is then mediated by ATP-dependent chaperones, such as DnaK 
with its co-chaperone DnaJ and the GroEL/ES chaperonins (Young et al., 2004). 
 The eukaryotic cytosol lacks trigger factor, instead NAC (nascent chain 
associated complex) and, in yeast, RAC (ribosome-associated complex) are though to 
interact with the newly synthesized protein as it emerges from the ribosome.  
 The central component of the cellular chaperone network is formed by the large 
family of ubiquitous and highly conserved Hsp70 chaperones together with their 
Hsp40 co-chaperones and nucleotide exchange factors. Hsp70 chaperones are ATPases 
which support protein folding through active cycles of binding and release and 
additionally exert multiple other important functions in the cell. The 70 kDa family of 
molecular chaperones will be discussed in greater detail in the following chapter.  
 The chaperonins are a family of sequence-related proteins of about 60 kDa 
which associate into large, multimeric double-ring complexes that enclose a central 
cavity in each ring (Agashe and Hartl, 2000). Partially folded substrates are 
encapsulated in these central cavities, where folding can occur shielded from the 
cellular environment. Two classes of chaperonins can be distinguished. Group I 
chaperonins, represented by the bacterial GroEL as well as Hsp60 from mitochondria 
and chloroplasts, function in conjunction with a ring-shaped co-factor, GroES or 
Hsp10, which forms a lid on the folding cage (Frydman, 2001). In contrast, Group II 
chaperonins of the eukaryotic (and archaeal) cytosol do not interact  with a lid-like co-
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factor, possibly because the function of GroES is carried out by the chaperonin itself 
(Agashe and Hartl, 2000). 
 The Hsp90 family is a eukaryotic chaperone system that acts downstream of 
Hsp70/Hsp40 and binds a more restricted subset of substrate proteins in the cell 
(Nathan et al., 1997). It is highly specific for signal transduction molecules such as 
steroid hormone receptors and protein kinases, and is actively involved in the 
maturation of these signaling molecules (Smith, 2000). 
 An additional class of stress-inducible molecular chaperones is referred to as 
the small heat shock proteins. Eukaryotic representatives of this family, which bind 
unfolded proteins and prevent their aggregation are Hsp12, Hsp42 and the mammalian 
α-crystallin. 
 Other chaperones include the highly conserved Hsp100/Clp family members, 
which are often part of an ATP-dependant protein degradation system, as well as 
specialized chaperones in various cellular compartments, such as calreticulin and 
calnexin of the endoplasmic reticulum. 
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II.1.3 The Hsp70 family of chaperones 
 Hsp70 chaperones are monomeric, ~70 kDa proteins which are present not only 
in the bacterial, archaeal and eukaryotic cytosol, but also in the eukaryotic nucleus, 
mitochondria, chloroplasts and endoplasmic reticulum (Barral et al., 2004).  In 
addition to their functions in de novo protein folding and prevention of aggregation, 
Hsp70 chaperones are involved in various other cellular processes such as protein 
targeting and membrane translocation, disassembly of oligomeric protein structures, 
protein degradation and control of regulatory protein activity (Bukau and Horwich, 
1998; Mayer and Bukau, 2005). The cytosol of higher eukaryotes contains both 
constitutively expressed (Hsc70) and stress-inducible (Hsp70) members of this 
chaperone family, which exert their specialized functions together with their co-
chaperones of the J-domain protein (Hsp40) family and nucleotide exchange factors. 
 Hsp70 chaperones consist of two major functional domains, a highly conserved 
N-terminal ATPase domain of 45 kDa and a less conserved C-terminal substrate-
binding domain of 25 kDa. The substrate binding domain can be further subdivided 
into a β-sandwich domain of 15 kDa with a peptide binding cleft and a 10 kDa 
carboxy-terminal α-helical lid domain (Mayer and Bukau, 2005; Zhang and 
Zuiderweg, 2004).  
 The structures of both domains have been solved separately and recently the 
structure of a truncated bovine Hsc70 has been determined (Jiang et al., 2005). The 
ATPase domain of Hsp70 proteins consists of two lobes with a deep nucleotide 
binding cleft between them (Flaherty et al., 1990). This structure is highly conserved 
from bacteria (E.coli) to humans and shows striking similarity to actin and equivalent 
regions in hexokinase and glycerol kinase (Flaherty et al., 1990; Flaherty et al., 1991). 
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Figure 2: Structures of the domains of Hsp70 
 
(A) The N-terminal ATPase domain of bovine Hsc70 with bound ADP (PDB code 3HSC). (B) The C-
terminal substrate binding domain E.coli DnaK in complex with a peptide substrate (PDB code 1DKZ). 
 
   
In vivo, the binding cycle of Hsp70/DnaK is assisted by co-chaperones of the 
Hsp40/DnaJ class and nucleotide exchange factors (GrpE for DnaK). Hsp40 
chaperones themselves bind substrate and are thought to deliver unfolded polypeptide 
chains to the Hsp70s. The reaction cycle of Hsp70 proteins, best understood for the 
bacterial DnaK, is depicted in Figure 3. 
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Figure 3: Model of the Hsp70 reaction cycle in polypeptide binding and release as 
exemplified by the bacterial DnaK, DnaJ and GrpE. Adapted from (Agashe and Hartl, 
2000) 
 
(A) DnaJ can bind to an unfolded polypeptide and then present it to the ATP-bound form of DnaK. (B) 
The stimulation of ATP hydrolysis resulting from the interaction of DnaK with both peptide substrate and 
DnaJ causes DnaK to rapidly attain its ADP-bound state that stably binds to the polypeptide substrate. 
(C) in E. coli and in mitochondria a second essential cofactor, GrpE, then catalyzes the exchange of the 
bound ADP for ATP. (D) This action reverts DnaK to its low substrate affinity state and facilitates the 
release of the substrate. 
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II.2 Innate and adaptive immune system 
 The mammalian immune system is commonly described as consisting of two 
interacting parts: the innate and the adaptive immune systems. Innate immunity 
provides a “first-line” of defense to invading pathogens. It includes physical barriers 
such as skin and mucous tissue as well as constitutively expressed anti-microbial 
molecules such as lysozyme and antimicrobial peptides. The cellular components of 
the innate immune system include phagocytic cells, the most common of which being 
macrophages, dendritic cells and neutrophils.  A limited amount of cell-surface 
receptors recognize conserved microbial molecules, such as LPS, peptidoglycan and 
unmethylated DNA, and induce signal transduction pathways resulting in the secretion 
of various cytokines such as IL-12, CD40L, IL-1, IFN I and TNF, which facilitate an 
effective immune response. 
 Additionally, several classes of anti-microbial proteins can be activated upon 
encounter with a pathogen, e.g. the complement system, which, once active, recruits 
inflammatory cells, coats pathogens to make them more easily phagocytosed, and 
forms destructive pores in the surfaces of pathogens (Beutler et al, 2004).  
 While being highly effective against certain pathogens, the innate immune 
system fails to recognize many bacteria and viruses, which have evolved to escape this 
type of immune recognition e.g. by masking typical conserved surface molecules. 
Vertebrates have developed an additional set of protective mechanisms that encounter 
such pathogens, namely the adaptive immune system.  
 Adaptive, or acquired immune mechanisms are responsible for immunologic 
memory, i.e. the ability to mount a stronger and more effective immune response 
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against an antigen after having survived an initial encounter with it, thus resulting in 
long-lasting protection against certain pathogens.  
 Unlike innate immunity, adaptive immune responses are highly specific to the 
particular antigen that induced them. Specificity relies on the recognition of antigenic 
material by lymphocytes, the principal active components of the adaptive immune 
system. These cells represent a clonally diverse defense repertoire in which each 
lymphocyte bears multiple copies of a unique antigen receptor (Cooper and Alder, 
2006), formed by somatic rearrangement on the DNA level. 
 B-Lymphocytes (bone marrow derived) recognize exposed determinants 
(epitopes) of intact molecules, including surface protein and carbohydrate moieties of 
invasive microbes (Cooper and Alder, 2006) and respond, once activated, with the 
secretion of antibodies specific for the encountered antigen. 
 T-Lymphocytes (thymus derived), on the other hand, recognize antigens only 
as fragments displayed by membrane bound molecules of the major histocompatability 
complex (MHC) in a process termed antigen presentation. The CD8+ subset of T-cells 
recognizes protein antigens as peptides presented by molecules of the class I MHC,  
and can directly destroy cells infected with viruses (cytotoxic T-cells).  CD4+ T-cells, 
on the other hand, recognize peptides complexed to MHC class II molecules, and act 
indirectly by activating B lymphocytes to produce antibodies and macrophages to 
destroy bacteria (Robertson, 1998) (helper T-cells). 
 MHC class I and class II molecules are highly polymorphic protein complexes, 
with the variable amino acids being concentrated in the peptide binding groove. This 
polymorphism, together with the co-expression of MHC molecules from multiple 
genes, enables the MHC molecules of any given individual to bind a wide range of 
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peptides, which can then be efficiently recognized by the highly variable antigen 
receptors of  T-Lymphocytes (Robertson, 1998). 
 
II.2.1 MHC class I antigen presentation 
 MHC class I molecules of higher organisms are expressed on the surface of 
virtually all nucleated cells (Pamer and Cresswell, 1998). They facilitate the 
immunosurveillance of processes within these cells through continuous display of 
peptide fragments derived from intracellular polypeptides, thus alarming the immune 
system in case of viral infection or oncogenic transformation.  
 Mature, membrane associated MHC class I molecules consist of three 
noncovalently linked components (Figure 4). The heavy chain (α-chain), a 
polymorphic product of one of the MHC class I genes (Pamer and Cresswell, 1998), is 
a membrane-spanning glycoprotein and forms the binding groove for a short peptide of 
8-10 amino acids. The associated light chain (β2-microglobulin, β2m) is a small soluble 
protein encoded outside the MHC locus (York and Rock, 1996). The peptide binding 
groove formed by the α1 and α2 domains is generally long enough to harbor a peptide 
of 8 or 9 amino acids in extended conformation, but longer peptides can also fit by 
bulging partly out of the groove.  
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Figure 4: Composition and structure of MHC class I molecules 
(A) Model of a typical MHC class I molecule (adapted from (Janeway, 1997)). (B) Murine H-2k(b) with 
SIINFEKL peptide, PDB code 1VAC (from http://www.rcsb.org). 
 
 
 The displayed peptides are derived, in the classical pathway of MHC class I 
antigen presentation, from intracellular proteins which have been processed by the 
proteasome (Figure 5). The proteasomal products (or peptides generated by other 
means) are then translocated into the endoplasmic reticulum (ER) by the transporter 
associated with antigen processing (TAP), a member of the ATP-binding cassette 
(ABC) transporter family, where they can be further trimmed by resident peptidases 
(Serwold et al., 2001).  
 Antigenic peptides in the ER are loaded on pre-assembled MHC class I – β2m 
heterodimers, which are then released from TAP and transported to the cell surface, 
where they can be recognized by surveilling lymphocytes. 
B A 
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Figure 5: Assembly of MHC class I molecules 
 
  
 This mechanism, by which most cells display peptides derived from genes 
expressed within the cell, allows the CD8+ T cells of the immune system to identify 
cells that are synthesizing abnormal genes (viral or mutant) and eliminate them (Rock 
and Shen, 2005). 
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II.2.2 MHC class II antigen presentation 
 Unlike intracellular antigens, peptides derived from extracellular pathogens are 
presented mainly by a specialized subset of immune cells, the MHC class II positive 
professional antigen presenting cells (pAPCs). B-cells, macrophages and dendritic 
cells belong to this cell group and possess a machinery specialized on uptake and 
processing of extracellular material and its presentation on MHC class II molecules.   
 MHC class II molecules are heterodimers composed of membrane-anchored α 
and β chains (Madden, 1995), the peptide binding groove being formed by the α1 and 
β1 domains (Figure 6). 
 Class II bound peptides can extend beyond class I bound peptides at both the 
N- and C-termini (Madden, 1995), with nine residues being bound within the class II 
groove and additional amino- and carboxy-terminal freedom (Jones, 1997).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: The structure of MHC class II molecules  
(A) Model of a typical MHC class II molecule (adapted from (Janeway, 1997)). (B) structure of an MHC 
class II molecule displaying a peptide, PDB code 2IAD (from http://www.rcsb.org). 
 
A B 
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 The MHC class II αβ heterodimers assemble in the ER with a third molecule, 
the invariant chain (Ii), which serves both as a targeting subunit and stabilizer of the 
peptide binding site (Watts, 1997). After transport to the trans-golgi network, the MHC 
class II-Ii complexes are targeted to vesicles within the endocytic pathway due to 
sorting signals present in the Ii cytoplasmic tail. In such vesicles, Ii is degraded, 
leaving a fragment of it in the peptide binding cleft of the MHC class II complex 
(Bryant and Ploegh, 2004). Peptide loading then occurs in late endocytic vesicles, in 
which epitopes are generated through proteolytic cleavage of endocytosed material. 
Loaded MHC class II molecules are subsequently transported to the cell surface 
(Watts, 2004).  
 
II.2.3  Antigen cross-presentation 
 The presence of the appropriate MHC-peptide complex on the surface of virally 
infected or tumor cells is sufficient to engage committed CD8+ killer T cells to destroy 
them (Ploegh, 2004). However, naïve CD8+ cells must first be stimulated (primed) by 
antigen presented on the MHC class I molecules of professional antigen-presenting 
cells before they can clonally expand and destroy cells synthesizing foreign or mutant 
antigen. DCs and possibly some macrophages (Brode and Macary, 2004) are the only 
pAPCs that are capable of  priming naïve CD8+ (and CD4+) cells: they express the 
necessary co-stimulatory molecules such as CD86, CD80 and CD40. A T-cell that 
receives both signals (antigen and co-stimulation) will become activated and produce 
cytokines, proliferate and differentiate into an effector cell. 
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 But how does the immune system initiate a response against viruses that do not 
infect professional APCs or against malignant not-APC cells? Most immunologists 
now agree that the key is cross-presentation (cross priming) (Ploegh, 2004).  
 First described by Michael  J. Bevan (Bevan, 1976a; Bevan, 1976b), cross-
presentation is the process of uptake of exogenous material by APCs, followed by 
processing and subsequent presentation of the antigens on the cells’ MHC class I 
molecules. In vivo, DCs acquire antigens from infected or transformed cells in the 
periphery, and then migrate to the lymph nodes where they display antigenic peptides 
in association with MHC class I molecules (Groothuis and Neefjes, 2005). Cross-
priming describes the resulting stimulation of CTL responses. 
 Multiple routes for cross-presentation of antigenic material have been described 
in DCs and Mφs. Internalization of exogenous antigens can be accomplished by 
endocytosis, pinocytosis, phagocytosis and macropinocytosis, the mode of uptake 
being primarily influenced by the character of the antigen. Even uptake of intracellular 
peptides through gap junctions has recently been proposed as an additional mechanism 
of antigen acquisition by cross-presenting cells (Neijssen et al., 2005).  
 A large number of studies performed on the mechanism of cross-presentation 
have revealed crucial roles for TAP and the proteasome, which would imply that the 
internalized antigens or peptides derived from them gain access to the cytosol of the 
cross-presenting cell (Figure 7). In this so-called “endosome-to-cytosol pathway”, 
exogenous antigens can further follow the regular pathway of MHC class I antigen 
presentation (proteasome, TAP, ER), ultimately leading to their display on class I 
molecules of the antigen presenting cell.  
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 Other reports have described an intersection between the recycling pathway of 
cellular class I molecules and endosomes/lysosomes which carry exogenous antigen 
(Gromme et al., 1999). In this model, antigens would be degraded by endocytic 
proteases, such as cathepsin S, rather than the proteasome (Groothuis and Neefjes, 
2005), and subsequently become loaded on class I molecules within the endosomal 
compartment. 
 
 
 
Figure 7: Possible pathways for MHC class I cross-presentation 
 
(A) Endosome-to-cytosol pathway: Exogenous antigens gain access to the cytosol of the antigen 
presenting cell, from which they follow the classical MHC class I presentation pathway. (B) Recycling 
pathway: exogenous antigen carrying endosomes fuse with recycling MHC I – containing endosomes, 
where peptide load can be exchanged. (C) ER-phagosome model: ER contributes membrane to the 
phagosome. Exogenous antigen is exported into the cytosol through ERAD and back into the phagosome 
through TAP. (D) Gap junctions allow direct transfer of peptides from cancer/infected cells into the 
cytosol of pAPCs. 
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 Recently, an alternative model for cross-presentation has become popular 
(Gagnon et al., 2002; Guermonprez et al., 2003; Houde et al., 2003). In the so-called 
“ER-phagosome model”, the endoplasmic reticulum is thought to contribute membrane 
for the formation of phagosomes. Endocytic vesicles formed by this mechanism then 
contain the complete ER-based machinery necessary for MHC class I antigen 
presentation, including the Sec61 pore complex necessary for translocation of antigens 
into the cytosol. This model offers a new mechanistic explanation for MHC class I 
cross-presentation, but has recently been questioned (Groothuis and Neefjes, 2005; 
Touret et al., 2005). 
 Taken together, there is no clearly defined pathway known, until now, for 
antigen cross-presentation, but it rather seems that the pathway taken is dependent on 
the nature of the antigen. However, it is now clear that cross-presentation is a major 
mechanism for the immune surveillance of tissues. Importantly, in vivo, cross-
presentation alone is not sufficient to initiate a protective immune response against the 
antigen. A second stimulus, leading to activation and maturation of the pAPC, is 
necessary to establish immunity rather than tolerance. Such a signal can be provided 
by adjuvants of bacterial origin, or, as recently described, by certain members of the 
heat shock family of proteins. 
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II.3 HSPs as key players of the immune system 
 In addition to the well-established role of molecular chaperones and heat shock 
proteins in the folding and re-folding of newly synthesized or misfolded proteins, the 
participation of HSPs in processes of the immune system has drawn much attention 
from researchers in the past years.  
 Directly related to the chaperoning properties of heat shock proteins is their 
participation in the intracellular events that lead to antigen presentation, such as 
degradation of proteins by the proteasome, transport to the endoplasmic reticulum, and 
chaperoning of MHC-antigen complexes within the ER and the secretory pathway. 
 Additionally, some chaperones have been found to serve as strong mediators of 
innate immune responses. The interaction of HSPs with cell surface receptors on 
antigen presenting cells has been shown to result in the secretion of inflammatory 
cytokines and nitric oxide by macrophages and dendritic cells, chemokines by 
macrophages, up-regulation of maturation markers on DCs  and migration of DCs to 
draining lymph nodes (Binder et al., 2004). By virtue of these properties, Hsp70 has 
been clinically employed as an adjuvant in combination with other treatments to 
activate APC and break tolerance to tumor-associated antigens (Calderwood et al., 
2005a; Srivastava, 2002a) 
 Of high medical relevance and the key basis of this study is the role that has 
been attributed to heat shock proteins in tumor rejection, which will be described in 
more detail in the following chapter.  
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II.3.1 Role of Hsp70 in anti-tumor immunity 
 The idea that a possible treatment or prevention of cancer could be provided 
through immunization dates back to the 1940s and 50s when several groups (Gross, 
1943; Prehn and Main, 1957) reported that tumors could be immunogenic in syngeneic 
mice (Klein, 2001). Later, the experiments of Klein et al. (Klein et al., 1960) 
demonstrated the extraordinary phenomenon that one could immunize against 
syngeneic tumors in the same manner as one could against smallpox and polio viruses 
(Srivastava, 2002a). In contrast to viruses, the tumors were of self origin and yet were 
immunogenic. As the individual tumors were not cross-reactive, it was concluded that 
the tumor-specific antigens were individually rather than commonly tumor-specific 
(Srivastava, 2002a). 
 Following these exciting discoveries, a laborious search for the tumor-specific 
antigens began, revealing, with a few exceptions, molecules that were generally shared 
between cancers and normal tissues but no truly cancer-specific molecules (Binder et 
al., 2001).   
 In the 1980s, DuBois et al. (DuBois et al., 1982) and later Pramod Srivastava 
and co-workers (DeLeo and Srivastava, 1985; Palladino et al., 1987; Srivastava et al., 
1986) finally managed to identify tumor rejection molecules common to cancers of 
divers origins. Surprisingly, all the well-characterized molecules described by this 
group turned out to be heat shock proteins of the hsp90, hsp70, calreticulin, or the 
grp170 family (Basu and Srivastava, 2000). They were able to show that homogeneous 
preparations of certain HSPs which were isolated from cancer cells elicited immunity 
to subsequent challenges with the cancer of origin, while corresponding preparations 
from normal cells did not (Srivastava, 2002b).  
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 As the HSP preparations used to immunize were homogenous by all criteria 
tested, the idea arose that low molecular weight substances, at that time not detectable 
by polyacrylamide gel electrophoresis, were associated with HSPs and responsible for 
the specific immunogenicity of HSP preparations (Srivastava and Amato, 2001; 
Srivastava and Heike, 1991; Srivastava and Maki, 1991). This was later proven when 
the same group showed that depletion of peptides from tumor-protective Hsp70 
through treatment of an immunogenic Hsp70 population with ATP rendered them 
ineffective in immunizing against cancer cells (Udono and Srivastava, 1993).  
The association of Hsp70 (and gp96) with antigenic peptides was later shown in vivo, 
ruling out speculations that the observed association of Hsp70 and gp96 with antigenic 
peptides could be the result of an artifact occurring after cell lysis and during 
purification of the HSPs (Menoret et al., 1999).  
 Importantly, immunogenic HSP-peptide complexes can also be generated in 
vitro – Blachere et al. reconstituted Hsp70-peptide complexes and showed that while 
HSPs alone and peptides alone were not immunogenic, HSP-peptide complexes 
elicited  MHC class I  restricted, antigen-specific CD8+ CTL responses (Blachere et 
al., 1997). Blachere et al. also demonstrated that the quantity of peptide complexed to 
HSP molecules required for successful immunization is extremely small - as little as a 
few hundred picograms of peptide, if complexed to HSPs, were found to be sufficient 
to immunize. These properties make HSPs powerful adjuvants for the generation of 
CD8+ responses and the first adjuvants of mammalian origin (Srivastava, 2002b). 
 Tumor-derived HSP-peptide complexes as well as artificially reconstituted 
HSP-peptide complexes (Hsp70 and gp96) are now finding increasing and effective 
use in tumor immunotherapy (Calderwood et al., 2005b). Similarly, potent anti-viral 
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responses have been generated through the administration of HSP-peptide complexes. 
HSP-based tumor and antiviral vaccines have been highly successful in animal models 
and are currently undergoing testing in phase I, II and III clinical trials.  
 
II.3.2 Hsp70 as a chaperone of adaptive immunity 
 The mechanism through which Hsp70-peptide complexes elicit anti-tumor and 
anti-viral responses has been delineated in some detail (Binder et al., 2004). Hsp70 is 
thought to become associated with tumor or viral antigens after their release into the 
cytoplasm by the proteasome. A number of studies have addressed the peptide 
sequence binding preferences of HSP70 proteins and indicated a similar peptide 
binding preference for MHC class I, e.g. the participation of hydrophobic and basic 
amino acids (Calderwood et al., 2005b; Flynn et al., 1989; Fourie et al., 1994; 
Gragerov and Gottesman, 1994; Gragerov et al., 1994; Wu and Wang, 1999). 
 Heat shock protein levels are increased during stress, and Hsp70 expression 
becomes deregulated in many types of cancer, resulting in elevated Hsp70 levels under 
non-stress conditions. As shown by Basu and co-workers (Basu et al., 2000), 
chaperone-peptide complexes get released during necrotic (but not apoptotic) cell 
death as occurs in cancers and virally infected cells, and the terminal stages of necrosis 
may favor antigen binding by Hsp70, since intracellular ATP levels decline and 
peptides become locked onto the ADP-associated HSP70 (Calderwood, 2005; 
Calderwood et al., 2005b). Indeed, a number of pathological conditions result in an 
increased Hsp70 level in the blood stream and the production of anti-Hsp70 antibodies. 
Hsp70 molecules, when released into the blood stream from necrotic cells, carry with 
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them a repertoire of peptides from their cell of origin, including peptides derived from 
mutated or re-expressed embryonic or developmental antigens.  
 The extremely low quantity of HSP-complexed peptide needed for 
immunization suggested that these molecules were doing something more than simply 
protecting the peptides from degradation or other such physical dangers, and the 
general biological principle that extraordinary efficiencies are often achieved through 
specific receptors was soon proven in this case (Srivastava, 2002a). 
 Multiple studies on Hsp70, gp96 and other chaperones have shown specific, 
saturable and competitive binding of these molecules to the cell surface of various cell 
types, most of them being professional antigen presenting cells (Arnold-Schild et al., 
1999; Castellino et al., 2000; Lipsker et al., 2002; Singh-Jasuja et al., 2000; 
Sondermann et al., 2000). The specific binding of  HSP-peptide complexes to antigen 
presenting cells is supported by the fact that the priming of immune responses by HSP-
peptide complexes is exquisitely sensitive to abrogation of function of antigen 
presenting cells (Srivastava, 2002a).  
 The binding of HSP-peptide complexes to the surface of APCs leads to their 
receptor-mediated endocytosis (Arnold-Schild et al., 1999; Castellino et al., 2000; 
Singh-Jasuja et al., 2000; Wassenberg et al., 1999), followed by  processing (if 
necessary) and cross-presentation of the chaperoned peptides on MHC class I 
molecules of the antigen presenting cell. This re-presentation of antigenic peptides, 
together with the adjuvant function of heat shock proteins, ultimately results in the 
described potent immune response.  
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 So far, a number of cell surface receptors for HSPs have been proposed, 
including uptake-receptors as well as such responsible for the stimulation of innate 
immune mechanisms by HSPs. CD91, a molecule also referred to as the LRP/α2-
macroglobulin receptor, has been proposed as an uptake receptor first for gp96, and 
later also for Hsp70, Hsp90 and calreticulin (Basu et al., 2001; Binder et al., 2000). 
The ability of CD91 to interact with these proteins although they share no structural 
similarity reflects the promiscuity of the receptor - at least 32 ligands have been 
published to date (Binder et al., 2004) - and raises concerns about the specificity of the 
determined interactions. CD40, previously described as a signaling receptor, was 
described to be an uptake-receptor for mycobacterial (Wang et al., 2001) and 
mammalian Hsp70 (Becker et al., 2002). 
A third candidate for the receptor-mediated endocytosis of Hsp70 was described by 
Delneste and colleagues, who identified LOX-1, a member of the same scavenger 
superfamily as CD91, as an additional receptor for endocytic uptake of Hsp70 and 
chaperoned peptides by human DCs (Binder et al., 2004; Delneste et al., 2002). 
 It is not yet well understood how Hsp70 interacts with cell-surface receptors on 
the molecular basis or which pathway within the cells is taken, ultimately leading to 
cross-presentation of chaperoned peptide. As previously mentioned, one study (Becker 
et al., 2002) described different binding affinities of Hsp70 to the surface of 
macrophages in dependence on the nucleotide state of the NBD, implicating a role of 
this domain in the interaction with the putative receptor CD40. Recently, another 
report, albeit on mycobacterial and not mammalian Hsp70, suggested that the C-
terminal substrate binding domain is necessary for interaction with APCs leading to 
cross-presentation (MacAry et al., 2004). The same group hat previously shown that 
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the C-terminal portion of Hsp70 (aa359-610) stimulates cytokine production and DC 
maturation (Lehner et al., 2004). 
 The pathway Hsp70 and its chaperoned peptide take within the cell is also not 
clearly defined. For Hsc70 it has been demonstrated that this pathway is dependent on 
the nature of the antigen and the requirement for further processing (Castellino et al., 
2000; Singh-Jasuja et al., 2001). If C-terminal processing of the peptide for transfer 
onto MHC molecules is required, re-presentation  is dependent on the activity of the 
proteasome and TAP. If C-terminal processing is not required, transfer of peptide from 
HSP to MHC can occur inside the endosome as confirmed by confocal microscopy. 
The involvement of individual endocytotic compartments such as described for the 
uptake and processing of other molecules has not been characterized until now. 
 
 
 
 
 
 
 
 
 
 
 
Introduction 28 
 
II.4 Aim of the project 
 The main focus of the project was to further delineate the mechanism by which 
Hsp70 chaperones peptides on the cross-presentation pathway. For a better 
understanding of this process, it was first necessary to investigate how the Hsp70 
molecule binds to the surface of the antigen presenting cell. Given the multiple roles of 
described for Hsp70 as a chaperone and an adjuvant, it was expected that multiple cell 
surface receptors exist. The interaction between Hsp70 and previously described 
(uptake) receptors was to be critically evaluated.  
 The question which domains of Hsp70 the molecule interact with the putative 
receptors was to be accessed, with emphasis laid on the cross-presenting ability of the 
chaperone. An assay was to be established which would allow to differentiate between 
interactions between Hsp70 and the cell surface which lead to cross-presentation of 
chaperoned peptide and such that do not.  
 Additionally, an assay was to be established that would allow the application of 
dominant-negative mutants of proteins participating in endocytotic events, thus 
allowing targeted intervention in intracellular processes leading to cross-presentation 
of Hsp70-bound peptides. 
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III MATERIALS AND METHODS 
III.1 Materials 
III.1.1 Chemicals  
 Unless stated otherwise, chemicals were purchased from Sigma-Aldrich 
(Steinheim, Germany) and were of “pro analysi” grade. 
 
Amersham Pharmacia Biotech (Freiburg, Germany): 
γ-32P-ATP 
Biochrom KG Seromed (Berlin, Germany):  
DMEM 
VLE-RPMI 1640 medium 
fetal calf serum (low endotoxin) 
L-glutamine, penicillin/streptomycin  
BioMol (Hamburg, Germany): 
IPTG 
HEPES 
BioRad (München, Germany):  
ethidium bromide 
Bradford Protein Assay 
BMA (Rockland, USA): 
AgaroseLE 
Calbiochem (Darmstadt, Germany): 
Chlorophenolred-β-D-galactopyroanoside 
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Difco (Heidelberg, Germany): 
Bacto Agar 
Bacto Peptone 
Bacto Tryptone 
Bacto Yeast Extract 
Fluka (Deisenhofen, Germany):  
ADP  
Dimethyle sulfoxide (DMSO) 
Invitrogen (Karlsruhe, Germany):  
2-mercaptoethanol 
Merck (Darmstadt, Germany): 
ampicillin 
2-mercaptoethanol 
EDTA 
Molecular Probes (Leiden, Netherlands):  
Alexa 488 protein labeling kit 
National Diagnostic (Hessle, England): 
Protogel (30 % Acrylamide, 0.8 % Bis-acrylamide) 
New England Biolabs (Frankfurt a.M., Germany):  
DNA ladder 100bp/1 kb 
restriction endonucleases and buffers 
T4 DNA ligase 
Pierce (Rockford, USA): 
BCA Protein Kit 
Coomassie Plus Protein Kit 
Promega (Mannheim, Germany) 
Wizard®PlusSV Miniprep Kit 
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Qiagen (Hilden, Germany): 
QIAprep Spin Mini prep kit 
QIAquick PCR purification and gel extraction kits 
QIAPrep EndoFree Plasmid Maxi Kit 
Roche (Basel, Switzerland):  
Ampicillin 
Complete protease inhibitor 
Dithiotreitol (DTT) 
EDTA-free protease inhibitor 
Shrimp Alkaline Phosphatase 
Roth (Karlsruhe, Germany):  
polyacrylamide/bisacrylamide solution 40 % (37.5 : 1) 
Serva (Heidelberg, Germany):  
Coomassie Serva Blue R 
Stratagene (La Jolla, USA):  
PfuTurboTM DNA Polymerase 
HerculaseTM DNA Polymerase 
QuickChangeTM site-directed mutagenisis kit 
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III.1.2 Materials and Instruments 
 
Abimed (Langenfeld, Germany):  
Gilson Pipetman 2, 10, 20, 100, 200 and 1000 µl 
Amersham Pharmacia Biotech (Freiburg, Germany): 
EPS 300 electrophoresis power supply 
prepacked chromatography columns: 
HiTrap chelating 1ml and 5ml 
HiPrep Desalting 5 ml 
NAP-5 Sephadex G25 
HiTrap Protein G 1ml 
Amicon (Beverly, MA, USA): 
concentration chambers (Centriprep, Centricon) 
vacuum filtration unit (0,2µm) 
Avestin (Mannheim, Germany):  
EmulsiFlex C5 homogenizer 
BD Biosciences (Heidelberg, Germany): 
FACSCalibur 
Cell culture plasticware 
Beckman (Munich, Germany): 
DU 640 UV/VIS Spectrophotometer 
Avanti J-25 centrifuge with rotors JLA 10.500 and JA 25.50 
Optima LE 80k ultracentrifuge with rotors SW28 Ti, SW 41 Ti, SW 55 Ti 
Biometra (Göttingen, Germany):  
T3 PCR-Thermocycler 
BioRad (München, Germany):  
MiniProtean 2 electrophoresis chamber 
Gene Pulser Xcell electroporation device with Gene Pulser electroporation cuvettes 
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Bio-Tek (Bad Friedrichshall, Germany) 
Synergy HT plate reader 
Branson Ultrasonics (Danbury, CT, USA): 
xxxsonifier 
Corning Inc (Schiphol-Rijk, the Netherlands):  
sterile cell culture pipettes 1 ml, 5 ml, 10 ml, 25 ml  
Eppendorf (Hamburg, Germany):  
centrifuges 5415C and 5417R, Thermomixer Comfort 
Fisher Scientific (Schwerte, Germany):  
Accumet Basic pH meter 
Fuji (Tokyo, Japan) :  
FLA 2000 Phosphoimager 
Mettler Toledo (Gießen, Germany):  
AG285 and PB602 balances 
Millipore (Eschborn, Germany):  
deionization system MilliQ plus PF 
Millex-HA filters 0.22 µm 
Steritop GP filter units 0.22µm 
New Brunswick Scientific (Nürtingen, Germany):  
Innova 4430 incubator 
Perkin Elmer (Rodgau, Germany): 
LS 50 B fluorescence spectrometer 
Raytest (Straubenhardt, Germany):  
AIDA version 2.31 gel imaging software 
Savant (Strasbourg, France):  
SGD 2000 slab gel dryer 
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III.1.3 Buffers and Media 
All buffers and media were prepared with ddH2O. Concentrations are given in weight 
per volume (w/v) for solid chemicals and in volume per volume (v/v) for liquids. 
 
III.1.3.1 Buffers 
 
ATP affinity buffer 1  50 mM Tris-HCl pH 7.5 
     50 mM KCl 
     5 mM MgCl2 
     (1 mM DTT) 
     (10 % Glycerol) 
 
ATP affinity buffer 2  50 mM Tris-HCl pH 7.5 
     500 mM KCl 
     5 mM MgCl2 
     (1 mM DTT) 
     (10 % Glycerol) 
 
ATPase Buffer   40 mM HEPES-KOH pH 7.4 
     300 mM KCl 
     10 mM MgCl2 
     2 mM DTT 
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Buffer Z    9 mM MgCl2 
     100mM 2-mercaptoethanol 
     0.125 % Nonidet P-40 (NP-40) 
     0.15 mM CPRG 
     freshly dissolved in PBS 
 
Denaturing wash buffer 1  50 mM Tris-HCl pH 7.5  
     6 M guanidinium-HCl 
     
Denaturing wash buffer 2  50 mM Tris-HCl pH 7.5 
     6 M guanidinium-HCl 
     20 mM imidazole 
 
Denaturing wash buffer 3  50 mM Tris-HCl pH 7.5 
     6 M guanidinium-HCl 
     500 mM NaCl 
      
Denaturing refolding buffer 20 mM Tris-HCl pH 7.5 
     500 mM NaCl 
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Hanks’ Balanced Salt Solution (HBSS) 
with calcium and magnesium 1.26 mM CaCl2 
     0.493 mM MgCl2 
     0.407 mM MgSO4 
     5.33 mM KCl 
     0.441 mM KH2PO4     
     4.17 mM NaHCO3 
     137.93 mM NaCl 
     0.338 mM Na2HPO4 
     5.56 mM D-Glucose 
 
HSP binding buffer   10mM MOPS 
     5mM MgCl2 
     150mM KCl 
     pH adjusted to 7.2 with KOH 
 
PBS     137 mM NaCl 
     2.7 mM KCl 
     4.3 mM Na2HPO4 
     1.4 mM KH2PO4 
     adjust pH to ~7,3 with HCl 
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PBG     137 mM NaCl 
     1 mM KCl 
     2 mM MgCl2  
     4,3 mM Na2HPO4 
     1,4 mM KH2PO4 
     adjust pH to ~7,3 with HCl 
 
Protein G Binding Buffer  20 mM Sodium Phosphate buffer , pH 7 
     100 mM NaCl 
 
Protein G Elution Buffer  100 mM Glycin*HCl 
     pH 2.7 adjusted with Tris pH 9 
 
SDS-PAGE electrophoresis buffer 50 mM Tris-HCl pH 8.3 
 380 mM glycine 
 0.1 % (w/v) SDS 
 
SDS-PAGE sample buffer (5x) 2 % SDS 
 60 mM Tris-Cl pH 6.8 
 24 % (v/v) glycerol 
 0.5 % (w/v) bromphenol blue 
 14.4 mM mercaptoethanol (added prior to use) 
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TAE-buffer    242 g/l Tris base 
     57.1 ml/l acetic acid 
     50 mM EDTA 
 
Transformation Buffer (TB) 10 mM Pipes 
     55 mM MnCl2 
     15 mM CaCl2 
     250 mM KCl2 
    pH 6.7 – 7 (KOH), adjusted prior to MnCl2 addition 
 
TLC running buffer   0.5 M formic acid 
     0.5 M LiCl 
 
III.1.3.2 Media 
 Unless stated otherwise, media were autoclaved after preparation. 
 
LB-medium 10 g/l bacto tryptone 
 5 g/l bacto yeast extract 
 5 g/l NaCl 
 pH adjusted to 7.4 with NaOH 
 
LB-agar 16 g/l bacto agar 
 dissolved in LB-medium 
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SOB-medium 20 g/l bacto tryptone 
 5 g/l bacto yeast extract 
 10 mM NaCl 
 2.5 mM KCl 
 10 mM MgCl2 
 10 mM MgSO4 
 
SOC-medium 20 g/l bacto tryptone 
 5 g/l bacto yeast extract 
 0.5 g/l NaCl 
 After autoclaving, supplement with sterile-filtered 
 10 mM MgCl2 
 10 mM MgSO4  
 0.4% (w/v) Glucose 
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III.1.4 Bacterial strains and mammalian cell lines  
 
Table 1: E.coli strains used in this study. 
Designation Reference 
DH5α Novagene 
BL21 (DE3) Novagene 
SURE Novagene 
XL1 Blue Stratagene 
 
 
Table 2: Mammalian cell lines used in this study. 
Designation Organism Tissue/ cell type 
Growth 
properties Properties Reference 
ANA-1 Mus musculus (mouse) macrophage adherent 
Adherent murine 
macrophage cell line, 
H-2b 
(Cox et al., 
1989) 
B3Z Mus musculus (mouse) 
T-lymphocyte 
hybrid suspension 
SIINFEKL/Kb 
specific, LacZ under 
the control of IL-2 
enhancer 
(Karttunen 
et al., 1992) 
DC2.4 Mus musculus (mouse) dendritic cells adherent H-2b 
(Shen et al., 
1997) 
COS-7 
Cercopithecus 
aethiops 
(African green 
monkey) 
kidney/ 
fibroblast adherent 
SV40 transformed, T 
antigen 
ATCC No.: 
CRL-1651 
HEK 293T Homo sapiens (human) 
kidney/ 
epithelial adherent 
Highly transfectable 
derivative of the 293 
cell line into which 
the gene for SV40 T-
antigen was inserted. 
ATCC No.: 
CRL-11268 
Raji Homo sapiens (human) 
Haematopoietic  
B lymphocyte suspension 
Express high levels of 
CD40 
ATCC No.: 
CCL-86 
Raw 264.7 Mus musculus (mouse) macrophage adherent H-2d 
ATTC-No.: 
 TIB-71 
Raw 309 
Cr.1 
Mus musculus 
(mouse) 
monocyte/ 
macrophage adherent H-2d, H-2b 
ATCC No.: 
TIB-69 
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III.1.5 Plasmids  
 
Table 3: Plasmids used in this study. 
ORF Vector Restriction sites Comments 
Hsp70 human Eco RI/Xho I 
N70 human Bam HI/ Xho I 
C70 human Bam HI/ Xho I 
Ova-Hsp70 Bam HI/ Xho I 
Ova-N70 
pProEx HTa 
(Invitrogen) 
Bam HI/Xho I 
N-terminal His6-purification tag, 
cleavable with TEV protease 
H-2K(b) murine pcDNA3.1 (Invitrogen) Eco R V 
Includes KOZAK sequence of 
K(b) gene 
ARF 6 human 
ARF 6 T27N 
ARF 6 Q67L 
pCMV-Tag2A 
(Stratagene) Eco RI N-terminal FLAG tag 
CD40 human pcDNA3  Nhe I/Xho I  
Dyn I human Wild type 
Dyn I K44E 
pcDNA3.1 
(Invitrogen) Xho I/Xba I Dominant negative mutant 
Rab 5 human Wild type 
Rab 5 S34N Dominant negative mutant 
Rab 5 Q79L 
pCX Eco RI 
Constitutively active mutant 
Rab 7 human Wild type 
Rab 7 T22N Dominant negative mutant 
Rab 7 N125I Dominant negative mutant 
Rab 7 Q67L 
pcDNA3.1 Hind III/Apa I 
Constitutively active mutant 
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III.1.6 Antibodies 
 
Table 4: Antibodies used in this study. 
Antibody Species Reference 
Primary antibodies 
CD40 human mouse Ancell 
CD40 murine hamster BD Biosciences 
H2-k(b)-
Biotin mouse BD Biosciences 
H2-k(b)-PE mouse BD Bioscience 
25D1.16 mouse (Pace et al., 1995) 
LRP/α2MR/ 
CD91 mouse Progen 
 
Secondary antibodies and reagents 
FITC anti 
mouse goat Dianova 
Streptavidin 
PE - BD Biosciences 
 
 
III.2 Molecular biological methods 
 Unless stated otherwise, E.coli cells were grown at 37 °C with vigorous 
shaking (220rpm). 
III.2.1 E.coli glycerol stocks 
 For long-term storage of bacteria, cells were grown to saturation over night in 
LB medium supplemented with appropriate antibiotics. 1.4 ml of culture were mixed 
with 0.6 ml sterile glycerol and transferred into cryovials for snap freezing in liquid 
nitrogen or dry ice/ethanol and storage at -80 °C.  
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III.2.2 Plasmid DNA purification, small scale 
 For purification of plasmid DNA, 5 ml LB medium supplemented with 
antibiotics were inoculated with a single E. coli colony harbouring the plasmid of 
interest and grown to saturation over night at 37 °C. Cells were harvested by 
centrifugation and DNA was extracted according to the manual of QIAprep Spin 
Miniprep Kit (Qiagen,  Hilden, Germany) or Wizard®PlusSV Miniprep Kit (Promega, 
Mannheim, Germany). 
 
III.2.3 Plasmid DNA purification, large scale 
 Plasmid DNA for transfection of mammalian cells was purified with the 
QIAPrep EndoFree Plasmid Maxi Kit (Qiagen, Hilden, Germany). Routinely, 250-
500 ml of LB medium supplemented with appropriate antibiotics were inoculated with 
5 ml over night culture grown to saturation. Cell pellets were harvested by 
centrifugation and plasmid DNA was extracted according to the manufacturer’s 
instructions. 
 
III.2.4 Optical density measurements  
 DNA concentration of purified plasmid DNA was measured by UV absorption 
spectroscopy at a wavelength of 260 nm, assuming that 1 A260 unit corresponds to 
50 µg double stranded DNA in H2O. 
 Optical density of E.coli cultures was determined at 600 nm.  
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III.2.5 DNA sequencing 
 Sequencing of plasmid DNA was performed by Sequiserve (Vaterstetten, 
Germany). 
 
III.2.6 Restriction digestion and ligation of DNA 
 Fragmentation of DNA for analysis and cloning was performed by digestion of 
plasmid DNA or PCR products with restriction endonucleases. Enzymes and buffers 
were supplied by New England Biolabs, Frankfurt a.M., Germany and used according 
to the manufacturer’s recommendations. Purified PCR products and vectors were 
digested 1 h – over night at 37 °C in a 50 µl reaction volume. Vectors were 
additionally de-phosphorylated with calf intestinal phosphates for 1 hour. DNA 
fragments were separated by preparative agarose gel electrophoresis and purified from 
gel slices using anion exchange chromatography (QIAquick Gel extraction kit, 
Qiagen) following the manufacturer’s instructions.  
 Ligation reactions typically contained a molar insert to vector ration of at least 
4:1 in a volume of 20 µl and were incubated over night at 16 °C. 
 
III.2.7 DNA agarose gel electrophoresis 
 Separation of DNA fragments for analysis or preparation was performed using 
a Horizon 58 electrophoresis chamber (Whatman) with an EPS 300 power supply 
(Pharmacia Biotech) operated at constant voltage of 80 – 120 V. Gels contained 1-2 % 
agarose in TAE Buffer and 1 µg/ml ethidium bromide for visualization of double-
stranded DNA. 
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III.2.8 Generation of chemically competent E.coli  
 E.coli competent for chemical transformation were generated by the method 
described in (Inoue et al., 1990). 250 ml SOB medium were inoculated from a starter 
culture grown over night in LB and cultured until an oD600 of approximately 0.6. 
Culture was chilled on ice for 10 min before harvesting the cells by centrifugation at 
2500 x g, 4 °C. Cell pellets were gently resuspended in 20 ml ice-cold transformation 
buffer and DMSO was added to a final concentration of 7 %. The suspension was 
chilled on ice for 10 min and subsequently aliquoted, snap-frozen in dry-ice/ethanol or 
liquid nitrogen and stored at -80 °C. Competent cells generated by this method resulted 
in approximately 5*106 CFU / µg plasmid DNA. 
 
III.2.9 Chemical transformation of E.coli 
 For transformation, 50 µl competent cells were thawed on ice and gently mixed 
with 10-100 ng plasmid DNA or 1 – 10 µl ligation reaction. After 20 min on ice, the 
suspension was heat shocked at 42 °C for 45 – 60 s and placed on ice for 2 min. After 
addition of 1 ml SOC medium, cells were incubated at 37 °C for 1 h with shaking. The 
cell suspension was subsequently plated on selective plates and incubated at 37 °C 
over night. 
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III.2.10 Generation of electro-competent E.coli 
 For higher efficiency of transformation, E.coli cells were made competent for 
electroporation. A 5 ml over-night culture of LB medium was inoculated with a single 
colony from a freshly streaked plate.  2.5 ml of this culture were then used to inoculate 
500 ml of LB medium, which was then allowed to grow until an oD600 ~ 0.6. Cells 
were harvested by centrifugation (20 min, 5000 x g, 2 °C) and washed twice with ice-
cold, sterile ddH2O (double pellet volume). Pellets were then resuspended in 10 % 
glycerol (pellet volume), aliquoted and frozen in a dry-ice/ethanol bath for storage at  
-80 °C. 
 
III.2.11 Electroporation of E.coli 
 Electro-competent cells were thawed on ice and 50 µl cell suspension per 
reaction was gently mixed with 10-100 ng, but not more that 2 µl, DNA. After 1 min 
on ice, cells were transferred into pre-chilled 2 mm gap electroporation cuvettes.  
Electroporation was performed with the following settings: 200 Ω, 25 µF, 2.5 kV. The 
cells were immediately taken up in 1 ml SOC medium and incubated for 30-60 min at 
37° with gentle shaking before being plated on agar plates.  
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III.3 Protein biochemical methods 
III.3.1 Determination of protein concentration 
 Protein concentration was spectrophotometrically at OD595 by using Bradford 
reagent (Pierce, Rockford, USA) (Bradford, 1976) and a BSA standard dilution series 
or at OD280 by applying the Lambert-Beer equation and the theoretical extinction 
coefficient (Pace et al., 1995). Extinktion coefficients were determined using the 
ProtParam tool at the Expasy server (http://www.expasy.ch). 
 
III.3.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 Proteins were analyzed by SDS PAGE under denaturing, reducing conditions 
(Laemmli, 1970). Samples were prepared by addition of 5x SDS PAGE sample buffer 
and heating to 96 °C for 5 min prior to loading onto the gel.  
 Stacking gels were made with 4 % and resolving gels contained 10 % or 12 % 
polyacrylamid (AA) (see table 5). Ammonium-peroxo-disulfate (APS) and N,N,N’,N’-
di-(dimethylamino)-ethane (TEMED) were adding immediately before casting the 
gels. Electrophoresis was carried out at constant current (40 mA – 150 mA per Gel) in 
electrophoresis buffer. 
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Table 5: Composition of stacking and separating gels for SDS-PAGE (10 ml). 
 Resolving gel  12  % AA 
Resolving gel  
10  % AA 
Stacking gel  
4 % AA 
30 % AA,  0.8 % bis-AA 4 ml 3.3 ml 1.3 ml 
1.5 M Tris-HCl, pH 8.8 2.5 ml 2.5 ml - 
0.5 M Tris-HCl, pH 6.8 - - 2.5 ml 
10 % SDS 0.1 ml 0.1 ml 0.1 ml 
H2O 3.4 ml 4.1 ml 6.1 ml 
TEMED 5 µl 5 µl 10 µl 
10 % APS 50 µl 50 µl 50µl 
 
 Following electrophoresis, gels were stained with Coomassie Staining Solution 
(0.1 % Coomassie Brilliant Blue R-250, 30 % methanol, 10 % acetic acid) and 
destained with 50 % methanol, 12 % acetic acid. 
 
III.3.3 Purification of Hsp70, N70 and C70 
 Full-length Hsp70 as well as the individual domains N70 and C70 were 
purified as soluble, his-tagged proteins from E.coli BL21. Bacterial cells transformed 
with the respective plasmids were plated on LBAmp-agar from glycerol stocks. Colonies 
were allowed to grow over night at 37 °C.  
 For the purification of full-length Hsp70,  single colonies were picked and used 
to inoculate 1 l of LBAmp medium, which was allowed to grow over night. The culture 
was then diluted into 5 l  LBAmp-medium and grown to an oD600 of 0.4-0.5. Protein 
expression was induced by addition of 1mM IPTG and allowed to proceed for 4 hours.  
 Bacterial cells were harvested by centrifugation for 20 min at 3000 x g and 
4 °C. From this step onwards, all procedures were carried out on ice or at 4 °C 
(centrifugation steps) and with ice-cold material.  
Materials and Methods 49 
 
 For lysis of bacterial cells, pellets were resuspended in 50 ml PBS, 0.1 % 
Triton and complete EDTA-free protease inhibitor (Roche, Basel, Switzerland). The 
suspension was homogenized by four passages through a French Press (EmulsiFlex 
C5) operated at 10000-15000 psi.  
 Removal of cell debris was achieved through ultracentrifugation at 100 000 g 
for 45 min and subsequent filtration (0.45µm). Salt content of the cleared lysate was 
adjusted by addition of NaCl and imidazole to a final concentration of 0.5 M and 
10mM, respectively.  Lysate was then applied to a 5 ml HiTrap chelating column, 
which had been previously loaded with 0.1 M NiSO4, at a flow rate of 1 ml/min, 
powered by a peristaltic pump. The column was washed with 5 volumes of 50 mM 
Tris, pH 8.0, 0.5 M NaCl and bound His6-tagged protein was eluted with 50 mM Tris, 
pH 8.0, 50 mM NaCl, 0.5 M imidazole. 15 1 ml fractions were collected and aliquots 
were subjected to SDS page for quality and quantity control. Fractions containing 
significant amounts of pure His-Hsp70 were pooled and dialyzed against 4 l of ATP 
affinity buffer 1 containing DTT and glycerol, followed by ATP affinity 
chromatography. 
 The purification of the amino-terminal and carboxy-terminal domains of 
Hsp70, as well as Ova-Hsp70 were performed in the same manner with following 
modifications. 
 N70 was expressed in a total culture volume of 1.1 l, and a 1 ml HiTrap 
chelating column was used. Only the first 2 ml of the eluate were collected since the 
following fractions contained heavily precipitated material.  
 C70 was expressed in a culture volume of 4 l and harvested 3 h after induction. 
Fractions containing the first 50 ml of eluate were pooled and dialyzed twice against 4 
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l of either HSP binding buffer or PBG, both supplemented with 10 % glycerol and 1 
mM DTT. The purified protein was aliquoted and frozen in ethanol/dry ice. 
 Ova-Hsp70 was expressed in a culture volume of 1.1 l and ml 2-4 of the eluate 
were pooled and frozen after dialysis. 
 
III.3.4 Purification of Ova-N70 from inclusion bodies 
 Ova-N70 was expressed as insoluble his-tagged protein in a culture volume of 
1.1 l as described above. Cell pellets were resuspended in PBS supplemented with 
proteinase inhibitor (complete mini EDTA-free) and lysozyme (400 µg/ml) and 
incubated for 30 min with gentle agitation. Triton-X-100 was added to a final 
concentration of 1 % and cell suspension was subjected to three passages through the 
cell disrupter followed by five sonication steps. Three ultracentrifugation steps were 
carried out to isolate insoluble protein (30000g, 30 min, 4 °C). Final pellet was 
solubilized in 20 ml 6 M guanidinium-HCl, 50 mM Tris pH 7.5. The solubilized 
material was separated from cellular debris through ultracentrifugation (100000 g, 60 
min, 4 °C) and an aliquot was subjected to SDS PAGE for quality and quantity control. 
 Approximately 10 mg of His6-tagged protein were applied on a 1 ml HiTrap 
chelating column which had been loaded with NiSO4 and equilibrated with 6 M 
guanidium-HCl, 50 mM Tris pH 7.5. The column was washed with five volumes each 
of denaturing wash buffer 1, 2 and 3, followed by refolding of bound protein with 
denaturing refolding buffer. After an additional washing step with PBS, protein was 
eluted with 200 mM imidazole/PBS. Fractions containing ml 3 – 7 of eluate were 
pooled and dialyzed over night against HSP binding buffer supplemented with DTT 
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and glycerol. Sample was concentrated five-fold and centrifuged at 17000 x g to 
remove residual precipitates prior to aliquoting and freezing in an ethanol/dry ice bath. 
 
III.3.5 ATP affinity chromatography 
 Full-length Hsp70 as well as constructs containing the amino-terminal ATPase 
domain of the molecule were further purified through ATP affinity chromatography. 
For the generation of 2 mg ATP-agarose resin, 140 mg adenosin-5’-triphosphate-
agarose (Sigma) were incubated in 10 ml ATP affinity buffer 1 for 30 – 60 min on ice. 
After removal of residual liquid, the resin was washed twice with buffer 1 and 
centrifuged briefly to settle the gel. Protein solution was applied to the resin and 
allowed to bind on ice for 30 – 60 min with occasional agitation. After removal of 
unbound material, resin was washed twice with ATP affinity buffer 1, once with buffer 
2, and an additional time with buffer 1. Fractions of bound protein were eluted with 1 
ml buffer 1 supplemented with 3 mM ATP for 5 min on ice and analyzed by SDS 
PAGE. Pooled fractions containing pure protein were dialyzed against PBG or Hsp 
binding buffer containing DTT and glycerol, aliquoted and flash frozen on dry 
ice/ethanol. 
III.3.6 ATPase assay 
 ATPase assays were performed as described earlier (Obermann et al., 1998). 
ATPase activity was calculated from the amount of α-32P-ATP hydrolyzed in a certain 
time period. Proteins of interest were preheated to 30 °C in ATPase buffer and 
reactions were started by addition of ATP supplemented with 1 µC α32P-ATP. After 0, 
5, 20, 40 and 60 min, aliquots were removed, reactions were stopped  with 25 mM 
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EDTA pH 8.0 (final concentration), and flash frozen until further use. 1µl of each 
fraction was analyzed by thin layer chromatography (TLC) on PEI-cellulose plates 
(Merck) in TLC running buffer. Membranes were dried and exposed on detection 
plates (FuJi Film BAS-IP MS2040S). ATP and ADP spots were quantified using the 
Phosphoimager (FuJi Film FLA-2000) and the Aida software (Raytest). 
 
III.3.7 Labeling with Alexa dyes 
 Hsp70 and N70 were both labeled with Alexa-488 C5-maleimide (Molecular 
Probes). Typically, 1.5 mg of protein (2 mg/ml) were incubated with a 20 fold molar 
excess of reactive dye in PBS at 4 °C over night. Labeled protein was separated from 
free dye through extensive dialysis against ATP affinity buffer 1 before being 
subjected to ATP affinity chromatography.  Degree of labeling was determined by 
measuring the absorption spectra and applying Lambert-Beer’s equation as following: 
  
Protein concentration (M) = [A280 – A494 x 0.11] x dilution factor 
      Ε280 
 
Where E280 is the molar extinction coefficient of the protein and 0.11 is a correction 
factor to account for absorption of the dye at 280nM. 
 
moles dye per mole protein  =  A494 x dilution factor 
      71 000 x protein concentration (M) 
 
Where 71 000 is the approximate molar extinction coefficient of the Alexa Fluor 488 
dye at 494 nm. 
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III.3.8 Formation of Hsp70/Ova-BiP complexes 
 For loading of Hsp70 with Ova-BiP, 4.8 µM Hsp70 was incubated with 96 µM 
Ova-BiP in PBG supplemented with 100µM ATP in a final volume of 500 µl for 30 
min at 25 °C. Peptide loaded Hsp70 was stabilized by addition of 1 mM ADP and 
incubation at 25 °C continued for 2 h. Alternatively, a quicker loading protocol of 15 
min (ATP) and 25 min (ADP) at 37 °C resulted in similar efficiencies.  
 For separation of Hsp70/Ova-BiP complexes from free peptide, the 500 µl 
reactions were applied to Nap-5 gel filtration columns equilibrated with PBG. 
Complexes were eluted with 1 ml PBG, and drops 7 – 14, corresponding to µl 200 - 
470, contained Hsp70/Ova-BiP complexes but not free peptide. Immediately after 
elution, Hsp70/Ova-BiP complexes were utilized for cross-presentation assays.  
 
III.3.9 Formation of C70/Ova-BiP complexes  
 C70/Ova-BiP complexes were generated by incubation of 4.8 µM C70 with 96 
µM Ova-BiP in PBG in a final volume of 500 µl over night at 25 °C. 
 Separation from free peptide was accomplished as described for Hsp70, with 
the distinction that drops 5 – 14 were collected. 
 
III.3.10 Anisotropy measurements 
 Fluorescent anisotropy measurements were conducted in an LS 50 B 
fluorescence spectrometer (Perkin Elmer). For the measurement of anisotropy of 
FITC-Ova-BiP to Hsp70 or C70, the exitation maximum was set to 492 nm and the 
emission maximum to 519 nm, as determined by exitation- and emission scans. Slits 
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were set to 10 (exitation) and 20 (emission). For determination of binding constants, 
fluorescent peptide was incubated with increasing amounts of Hsp70 or C70 and with 
or without nucleotide for 30 min before end-point anisotropy readings were taken. 
Care was taken that r had reached stable values. For time-dependent binding studies, 
Hsp70 or C70 was incubated with fluorescent peptide and nucleotide at 25 °C directly 
in the cuvette, with continuous anisotropy readings taking place every 8 sec, until the 
reactions reached saturation. 
 
 
III.4 Cell biological methods 
III.4.1 Culturing of mammalian cells 
 Unless stated otherwise, murine cell lines were cultured in very low endotoxin 
(VLE)-RPMI 1640 containing stable glutamine, supplemented with 10 % fetal calf 
serum (FCS) and antibiotics (penicillin/streptomycin solution, Biochrom KG) at 
constant temperature, humidity and atmosphere (37 °C, 5 % CO2 and 95 % air). B3Z 
cells were additionally supplemented with 50 µM 2-mercaptoethanol (Invitrogen). 
 Human cell lines were cultured in DMEM supplemented with 10 % FCS, 
penicillin/streptomycin and 2 mM L-glutamine.  
 Cells growing in suspension were subcultured through addition of fresh, pre-
warmed medium as required (at least three times a week) and always on the day prior 
to an experiment. 
 For subculturing of adherent cells, medium was removed and the cell layer was 
rinsed once with PBS followed by a five minute incubation with trypsin/EDTA 
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solution. The cell suspension was then diluted as required through addition of fresh 
medium. 
 
III.4.2 Determination of cell number 
 Live cells were counted in a haemocytometer (Neubauer chamber) using trypan 
blue as a dye. 
 
III.4.3 Binding assay with fluorescently labeled Hsp70 and N70 
 For analysis of binding behavior of Hsp70 and N70, cultured cells were washed 
twice with PBS after removal of culture medium. Adherent cells were washed off the 
culture flask without trypsin to preserve proteinaceous surface structures. 5*105 – 
2*106 cells were incubated with 300 nM fluorescently labeled protein which had or 
had not previously been loaded with peptide and ADP. Surface binding of Hsp70-488 
and N70-488 was performed for 45 min on ice (in PBS) to prevent unspecific binding 
and uptake events. Cells were washed three times in PBS containing 1 % FCS and 
cross-linked with 2 % PFA/PBS, before being subjected to FACS analysis.  
 
III.4.4 Competition experiments 
 Raw 264.7 macrophages were incubated with 1 µM labeled Hsp70 (ADP) in 
the presence of a 10-fold excess of unlabeled Hsp70, N70 or C70 in the presence of 
BSA for 30 min on ice. Cells were then washed three times with TBS, fixed with 3 % 
PFA and analyzed by confocal microscopy.  
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III.4.5 Antibody staining  
 For flow cytometry analysis, cultured cells were detached without the use of 
trypsin and washed once with PBS, followed by 30-45 min incubation with the 
primary antibodies. Cells were washed twice before application of secondary 
antibodies (when necessary), followed by an additional 30-45 min on ice and in the 
dark. After 3 washes with ice-cold PBS, cells were resuspended in 500 µl 2 % 
PFA/PBS and subjected to flow cytometry.  
 For fluorescence microscopy, cells were grown on cover slips to about 50 % 
confluency. Cells were incubated with labeled proteins and peptides for 30 min on ice, 
washed three times with TBS and fixed with 3 % PFA for 20 min. Prior to application, 
Hsp70 and its domains were loaded with 100µM ADP for 30 min at 37 °C. Samples 
were embedded in Mowiol and stored in the dark. 
 
III.4.6 Flow cytometry analysis 
 Fixed or unfixed cell suspensions at a concentration of 1*106/ml – 5*106/ml 
were analyzed in a FACSCaliburTM (BD Biosciences) with the Cellquest software. 
Live populations were gated as determined by size and light scattering properties in an 
FCS/SSC plot. At least a total of 10 000 events in the live cell gate were analyzed for 
surface fluorescence. Alexa-488 and FITC dyes were detected in with the machine’s 
FL-1 filter, while red fluorescent dyes such as PE and Alexa 595 were detected in FL2. 
Background fluorescence was measured in the absence of labeled protein. 
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III.4.7 Transient transfection of mammalian cells 
 Transient transfections of cultured mammalian cells were performed through 
electroporation in Gene Pulser Xcell device (Biorad, Munich, Germany). Detached 
cells were washed once with cold medium and 1*106 – 10*106 cells per transfection 
were resuspended in 400 µl DMEM supplemented with 25 % FCS. Cell suspensions 
were mixed gently with plasmid DNA (typically 10 µg per transfection) and 
transferred to pre-chilled 4 mm gap electroporation cuvettes. Cells were pulsed with 
the following settings:  
Table 6: Electroporation settings 
Cell line Setting Capacity Voltage Time constant 
HEK 293T exponential 950 µF 240 V variable 
Raw 264.7 time constant variable 280 V 30 ms 
 
 After electroporation, cells were allowed to recover at room temperature for 5 – 
20 min, washed once with medium, and plated. 
 
III.4.8 Lipopolysaccharid (LPS) treatment 
 For LPS treatment, macrophages were grown in medium supplemented with 
1 µg/ml, 10 µg/ml or 20 µg/ml LPS in medium over night. The endotoxin was then 
removed by multiple PBS washes. 
 
III.4.9 Cryopreservation and revitalisation 
 For storage of cell lines in liquid nitrogen, cells were detached without the use 
of trypsin, pelleted and resuspended in 10 % DMSO/FCS. After transfer into 
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cryopreservation vials, cells were frozen stepwise for 1 h at -20 °C, followed by 12 – 
26 h at -80 °C and final transfer to liquid N2. 
 Revitalisation of frozen cells was achieved through rapid warming of the cells 
at 37 °C. Cells were then washed once with warm medium and plated.  Medium was 
exchanged on the following day in order to remove residual DMSO. 
 
III.4.10 Cross-presentation assays 
 Cross-presentation assays were carried out in V-bottom 96 well plates. 5*104 
dendritic cells or macrophages were incubated together with the antigen of interest and 
5*104 B3Z cells in final volumes of 50 µl – 200 µl per well. All experiments were 
performed at least in duplicates, usually in triplicates. After 4 h at 37 °C, plates were 
centrifuged (450 x g) and supernatant was discarded. The pellets were washed once 
with PBS and resuspended in 180 µl freshly prepared Buffer Z supplemented with 
CPRG substrate per well. Sufficient lysis of the cells was achieved mechanically by 20 
fold pipetting of the suspension.  
 Plates were covered with self-sticking transparent foil and transferred into a 
pre-heated Synergy HT plate reader (Bio-Tek, Bad Friedrichshall, Germany). The 
enzymatic reaction was allowed to proceed at 37 °C for 4 hours, with kinetic readings 
taking place every 15 min. Absorbance was measured at 570 nm and 650 nm, and the 
difference between the two values was determined (delta OD). Enzymatic activity of 
beta-galactosidase usually reached saturation after 1-2 hours. For data evaluation, the 
delta OD of wells containing no antigen was set as 1.  
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IV RESULTS 
IV.1 Interaction of Hsp70 with the surface of APCs and non-
 APCs 
 Previous experiments performed in our and other laboratories had shown a 
necessity for receptor mediated endocytosis (RME) in cross-presentation of Hsp70-
chaperoned peptide. RME has been proposed as the reason for the extremely efficient 
immune response generated by such complexes in vivo, and a set of receptors such as 
CD40 and CD91 have been suggested to act as uptake receptors for Hsp70. 
 To further characterize the interaction of Hsp70 with the surface of mammalian 
cells, recombinant human Hsp70 was purified and labeled fluorescently with Alexa-
488, with a labeling efficiency of 2 molecules dye per molecule Hsp70. To ensure that 
labeling did not interfere with the molecular properties of Hsp70, ATPase assays were 
performed using labeled and unlabeled recombinant Hsp70 as well as Hsp70/Hsc70 
isolated from pig brain. Labeled and un-labeled protein was shown to be active and the 
activity was comparable to that of purified porcine protein (data not shown). 
 To visualize surface binding of the chaperone to mammalian cells, labeled 
Hsp70, in its ATP-, substrate-free form as well as in its substrate-bound, ADP-form, 
was incubated with a set of cultured mammalian cells of different origin. Cells were  
incubated in the presence of labeled Hsp70 at low temperature (on ice) to inhibit 
nonspecific endocytosis. Surface binding was visualized by FACS analysis or 
fluorescent microscopy after removal of unbound material. 
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IV.1.1 Conformation-dependent binding of Hsp70 to the surface of 
 APCs 
 ANA-1 murine macrophages, which have been previously shown to interact 
with the Hsp70 molecule, bound Hsp70 specifically (Figure 7A). Cos-7 cells, on the 
other hand, showed little or no cell surface staining through the Hsp70 molecule 
(Figure 7B), which implicates the participation of  specific, cell-type dependent 
receptors in the binding event. While macrophages are professional antigen-presenting 
cells, Cos-7 cells are simian kidney cells which are not considered to have any 
immune-stimulating or cross-presenting activity. Similar results were obtained with 
Raw 264.7 macrophages and CHO chinese hamster ovary cells as demonstrated by 
fluorescent microscopy (Figure 7C and D). Confocal analysis of Hsp70 binding to 
mammalian cells was performed in collaboration with Sandra Zitzler at the ZBH in 
Heidelberg, Germany. 
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Figure 7: Binding of labeled Hsp70 to the surface of cultured mammalian cells. 
 
 
(A) ANA-1 murine macrophages bind Hsp70 in its peptide-loaded, ADP-state but not in it’s empty, ATP 
state. Intensity of surface fluorescence (x-axis) is plotted against cell counts. (B) Cos-7 (simian kidney 
cells) do not show cell surface labeling through Hsp70, regardless of its nucleotide state. (C) Raw 264.7 
murine macrophages show clear surface staining with Alexa-488 labeled Hsp70 but not with labeled 
BSA. (D) CHO (chinese hamster ovary) cells do not bind Hsp70. 
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 Interestingly, there was a marked difference between the binding behaviors of 
the two nucleotide states of Hsp70. While little or no binding to the macrophage 
surface could be shown for the open conformation of the molecule, a population of 
cells showed clear interaction with substrate-loaded Hsp70 in its ADP-bound state 
(Figure 7A). As is known from structural studies, Hsp70 undergoes a marked change 
in its conformation in dependence on its nucleotide- and substrate state, with the ADP-
state representing tight substrate binding.  Experiments had shown that chaperones are 
released in vivo during necrosis such as occurs in cancer and viral infection, but not 
through regulated apoptotic processes. 
  Such necrotic cell death is characterized by ATP-loss in the cytosol, which 
would lead to stable binding of substrate by Hsp70 during cell lysis and stabilize the 
HSP-peptide complex. The preferable recognition of  the substrate-bound state of the 
chaperone by uptake receptors on antigen presenting cells could be a highly efficient 
mechanism to discriminate between empty and loaded Hsp70 molecules, preventing 
uptake of bulk material and leading to endocytosis only of cross-presentation 
competent, loaded chaperone molecules.  
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IV.1.2 Contribution of the Hsp70 SBD and NBD to the cell surface 
 interaction 
 To better understand the mechanism of specific, conformation-dependent 
binding of Hsp70 to cells of the immune system, it was necessary to explore which 
functional domain of the molecule promotes this interaction. As previous results had 
shown a clear dependence on nucleotide (and substrate-) state of Hsp70 for surface 
binding, the first question to be addressed was whether the nucleotide binding domain 
alone of Hsp70 could specifically interact with the surface of cultured mammalian 
cells.  
 The ATPase domain of human heat shock protein 70 was purified from E. coli 
BL21 as a soluble His-tagged protein through affinity chromatography and ATP-
agarose and labeled with Alexa 488 as described for Hsp70. ATPase activity of labeled 
protein was tested and found to be comparable to that of the unlabeled nucleotide-
binding domain of the protein.  
 As with the full-length protein, binding assays were performed to analyze 
specificity of N-domain interaction with different cell types. Again, a clear dependence 
on the nucleotide-state of the protein was observed (Figure 8). These results led to the 
initial assumption that it is the N-terminal ATPase domain of Hsp70 that is responsible 
for specific binding of the molecule to the surface of immune cells. However, it is 
important to note that the binding pattern of N70 seems to be a different one than that 
of the full-length molecule. While incubation of macrophages with labeled Hsp70 
leads to a smooth, homogenous labeling of the cells surface (Figure 7C), a more 
punctuate staining is observed with the amino terminal domain (Figure 8B). 
Results 64 
 
     
 
Figure 8: Interaction of the Hsp70 amino-terminal ATPase domain with ANA-1 and Raw 
264.7 macrophages. 
 
(A) ANA-1 macrophages bind Alexa-488 labeled N70 in a nucleotide-dependent manner. (B) Surface 
staining of Raw 264.7 macrophages with Alexa-488 labeled N70. (C) Alexa-488 labeled BSA shows no 
binding to the macrophage surface. 
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 The different labeling patterns observed for the full-length molecule and the 
amino-terminal ATPase domain indicated that additional regions of the Hsp70 
molecule may also play a role  in the interaction with cell surface receptors. In order to 
further characterize this phenomenon, the C-terminal substrate binding domain (C70) 
of Hsp70 was purified and labeled with Alexa-633. C70 showed clear binding to the 
surface of antigen presenting cells, with a punctuate binding pattern similar to that of 
the ATPase domain (Figure 9). The binding of the SBD as well as the NBD of the 
Hsp70 molecule to the surface of the same cells could explain the differences in the 
observed binding patterns. If different receptors are responsible for the binding of each 
domain, resulting in punctuate binding pattern, a combination of both N- and C-
terminus as supplied by the full-length molecule would result in the observed 
homogenous staining.  
 
 
 
 
 
Figure 9: Binding of the  substrate binding domain of Hsp70, C70, to the surface of 
macrophages. 
 
The C-terminal substrate binding domain interacts with the surface of Raw264.7 macrophages, resulting 
in a punctuate staining pattern similar to that of N70 and in contrast to the homogenous staining 
generated by the full-length molecule labeled with the same dye. 
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 Competition experiments were performed to investigate the binding properties 
of the respective domains. For this purpose, Raw 264.7 macrophages were incubated 
with 1µM fluorescently labeled Hsp70 or a mixture of labeled Hsp70 and unlabeled 
competitor for 30 min on ice. Cells were then washed and subjected to fluorescence 
microscopy. As expected for a specific, receptor-mediated interaction, the binding of 
labeled Hsp70 to Raw 264.7 macrophages could be fully competed with a 20x molar 
excess of the unlabeled molecule (Figure 10B).  
 
 
 
Figure 10: Only the combined application of both nucleotide- and substrate-binding 
domain can fully compete the binding of labeled Hsp70 to Raw264.7 cells. 
 
(A) Surface staining of Raw264.7 macrophages through fluorescently labeled Hsp70. (B) A 10-fold molar 
excess of unlabeled Hsp70  is sufficient to fully compete the binding of labeled Hsp70. In contrast to the 
full-length molecule, the individual domains are not able to fully outcompete Hsp70-binding (C) and (D), 
while the combination of both domains restores the competition (E). 
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 Importantly, an equally high concentration of the isolated NBD or SBD, 
respectively, could not fully compete the interaction with the full length molecule 
(Figure 10C and D), while a combination of both domains led to a complete loss of 
staining by the labeled full-length molecule (Figure 10E). All competition experiments 
were performed in the presence of a 10-fold excess of BSA to ensure specificity. 
 These competition experiments reinforced the hypothesis that both domains of 
the Hsp70 molecule play a role in cell surface interaction, leaving the question open 
which domain is necessary (and sufficient) to promote cross-presentation of the 
chaperoned peptide. 
 
IV.1.3 Role of the proposed receptors CD40 and CD91 in the 
 interaction of Hsp70 with the surface of mammalian cells. 
 As previously mentioned, several receptors have been implied in the interaction 
of Hsp70 with the surface of mammalian cells. CD40, a well-known signaling 
receptor, has been proposed as an uptake receptor for Hsp70, and the interaction 
between the two molecules has been mapped to the amino-terminus of the chaperone 
(Becker et al., 2002). In order to re-examine this interaction, ANA-1 macrophages, 
which have been shown to bind Hsp70 in a nucleotide dependent manner, were treated 
with lipopolysaccharide (LPS), which increases cell-surface expression of CD40, and 
analyzed for their ability to bind fluorescently labeled Hsp70.  As expected, LPS-
treatment resulted in an increase of CD40 expression by ANA-1 cells. Surprisingly, 
cell-surface interaction of the Hsp70 molecule was found to decrease after LPS-
treatment of the macrophages, and disappeared completely after application of a higher 
dose of the endotoxin (Figure 11). 
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Figure 11: LPS treatment of macrophages results in increased CD40 expression but 
loss of Hsp70 binding. 
 
ANA-1 macrophages were treated with indicated amounts of LPS over night before performing Hsp70 
binding studies. While the expression of CD40 on the macrophage surface was increased due to 
endotoxin application, the binding of labeled Hsp70 exhibited a concentration-dependent decrease after 
treatment of cells with LPS.   
Hsp70 binding CD40 expression 
100ng/ml LPS 
1µg/ml LPS 
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 Since treatment of macrophages with LPS has additional effects other than a 
rise in CD40 expression, a second method was chosen to confirm the findings that 
Hsp70-surface interaction is not dependent on CD40 as the sole receptor. HEK 293T 
cells, which are capable of expressing very high levels of protein when transfected 
with the appropriate vector, were chosen as a model system. Electroporation of the 
fibroblasts with a human CD40 construct resulted in very high surface expression of 
the molecule, as measured by the application of PE-labeled antibodies against hCD40 
and subsequent FACS analysis (Figure 12). Since the interaction of CD40 with Hsp70 
had been mapped to the amino-terminal domain of the molecule, transfected cells were 
analyzed for their capability to bind labeled N70 in a nucleotide-dependent manner.  
 As depicted in Figure 12A, the transfection of HEK 293T cells with the human 
CD40 construct was highly efficient, with virtually the entire population expressing the 
receptor. Nevertheless, the specific and nucleotide-dependent binding of the Hsp70 
amino-terminal domain did not increase upon expression of human CD40 on the cell 
surface. Taken together, it remains debatable whether CD40 has a relevant role in the 
interaction of Hsp70 with the surface of mammalian cells. It can not be excluded, 
however, that CD40 acts as a component of a multi-receptor complex, and an 
additional co-receptor would be necessary to promote functional interaction with 
Hsp70. 
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Figure 12: Over-expression of CD40 has no influence on the binding of fluorescently 
labeled N70 to the surface of  HEK293T cells. 
 
(A) High CD40 expression on the surface of transfected cells. Nucleotide-dependent binding of labeled 
ATPase domain to CD40 transfected (C) and mock transfected (B) cells is not influenced by over-
expression of the receptor.  
 
mock transfected 
CD40 transfected 
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transfected 
CD40 
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 In addition to CD40, CD91 has been proposed as a receptor not only for Hsp70, 
but also for gp96 and other chaperones, as well as multiple other ligands (Basu et al., 
2001). The interaction between Hsp70 and CD91 was re-examined in the lab of Felix 
Wieland. The group compared the two macrophage lines Raw 264.7 and Raw 309 Cr.1 
as well as CHO cells stably transfected with CD91 (CHO+CD91).  
 As shown for Ana-1 macrophages in this study, Raw 264.7 macrophages lost 
their capability to bind Hsp70 after LPS-treatment. Western blot analysis of cell 
membranes showed unaltered expression of CD91 on the macrophage surface, 
challenging the connection between Hsp70 binding and CD91 expression. 
 Raw 309 Cr.1 macrophages, on the other hand, had been described by Basu et 
al. as a cell line that does not express CD91 and, accordingly, does not bind Hsp70 or 
cross-present Hsp70-chaperoned peptide. In contrast to this perception, Felix 
Wieland’s group could show that the cells indeed did bind labeled Hsp70, and this 
binding was further increased through LPS treatment. Expression of CD91, on the 
other hand, was severely reduced after LPS treatment.  Our group performed 
experiments clearly showing that the macrophages were capable of cross-presenting 
peptide chaperoned by Hsp70, and this property was not diminished after LPS 
treatment (data not shown). 
 Taken together, these results clearly argue against CD91 as a receptor for 
Hsp70, as neither binding nor cross-presentation properties are affected by its presence 
or absence. 
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IV.2 Cross-presentation of peptide chaperoned by Hsp70 
 The highly effective immunization properties of Hsp70 rely on its ability to 
bind peptides and shuttle them to antigen presenting cells, resulting in receptor-
mediated uptake and subsequent cross-presentation of these peptides or fragments 
derived from them on MHC class molecules of the APCs. 
 In order to investigate the cross-presenting capabilities of Hsp70, an in-vitro 
system was established which allows loading of the chaperone with peptide and 
following the processing and presentation of the peptide by cultured antigen presenting 
cells. The model peptide chosen for this purpose, Ova-BiP, consists of a high affinity 
ligand for the peptide-binding site of Hsp70 (BiP) and a dominant T-cell epitope 
(Ova), connected by a glycine-serine-glycine linker.  The peptide (Figure 13A), 
originally described by Moroi and collegues (Moroi et al., 2000), was shown to induce 
cellular immunity in vitro and rejection of tumors in vivo when applied in complex 
with Hsp70. The primed CTL responses in mice were more potent than in those 
immunized with epitope (complexed to Hsp70) alone, supporting the concept that 
peptide must be bound to the chaperone in order to be efficiently cross-presented. 
Hsp70/Ova-BiP complex formation in vitro in the presence of ATP is saturable, with a 
calculated dissociation constant of 332nM for FITC-labeled peptide, and can be further 
stabilized through addition of a molar excess of ADP (Figure 13B). 
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Figure 13: Ova-Bip is an in-vitro substrate of Hsp70 
 
(A) Sequence of Ova-BiP: SIINFEKL is an ovalbumin-derived epitope for the murine MHC class I  
H-2k(b).  (B) In vitro loading of Hsp70 with hybrid peptide: FITC labeled Ova-BiP was incubated at room 
temperature for the indicated time in the presence of 100 µM ATP. Addition of 1 mM ADP further 
increases and stabilizes the substrate-loaded state of Hsp70. (C) Binding curve of FITC-Ova-BiP to 
Hsp70. 
 
 The generated Hsp70-peptide complexes can be separated from free peptide by 
gel filtration and administered to cultured dendritic cells or macrophages. The cells, 
capable of cross-presentation, take up the complexes and present, after processing the 
hybrid peptide, the SIINFEKL antigen on their MHC class I K(b) molecules. This 
cross-presentation can then be monitored by two methods. The murine antibody 25-
D1.16 specifically recognizes the SIINFEKL epitope when presented on H2-k(b) 
molecules. This antibody was purified from hybridoma supernatant and fluorescently 
labeled with Alexa 555, allowing detection of cross-presented model peptide by 
fluorescence microscopy or FACS.  
A 
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Results 74 
 
 For more efficient and better quantifiable detection of cross-presented antigen, 
the B3Z cell line was employed. Originally described by the group of Nilabh Shastri 
(Karttunen et al., 1992), B3Z is a Ovalbumin/k(b) specific T-cell hybridoma which is 
activated upon encounter of cells presenting SIINFEKL on their H2-k(b) molecules. 
Highly sensitive detection of T-cell activation is possible through a simple colorimetric 
assay. This assay makes use of a stably transfected lacZ reporter construct under the 
control of the nuclear factor of activated T cells (NF-AT) element of the human 
interleukin 2 (IL-2) enhancer. Due to this construct, occupancy of the TCR triggers not 
only the secretion of IL-2 but also the production and intracellular accumulation of 
lacZ, which can then be visualized by lysis of the T cells and their incubation with 
chromogenic substrates. 
 
IV.2.1 Peptide chaperoned by Hsp70 is cross-presented efficiently 
 by dendritic and macrophage cell lines 
 Using the described approach, it was possible to monitor the cross-presentation 
of Hsp70-chaperoned peptides by antigen-presenting cells. DC2.4, a murine dendritic 
cell line, and Raw 309, a murine macrophage cell line, were chosen for this purpose 
since they express the appropriate MHC class I haplotype and are professional antigen 
presenting cells capable of cross-presentation. As shown in Figure 14, Ova-BiP 
peptide, when complexed to Hsp70, was efficiently cross-presented by the antigen-
presenting cells at concentrations which are not sufficient for free peptide to be 
presented. The amount of Hsp70 molecules carrying peptide after separation from free 
peptide was estimated as 20%, as determined by the group of Felix Wieland (Stefan 
Hancke, personal communication) and in agreement with previously published data 
Results 75 
 
(Moroi et al., 2000). Hsp70-peptide complexes applied to the APCs did not contain 
free peptide (Figure 14B). Dendritic cells cross-presented Hsp70-bound peptide more 
efficiently than macrophages, which is not surprising given that DCs are thought of as 
the principle cross-presenting cells in vivo.  
  
 
 
 
 
 
Figure 14: Cross-presentation of Hsp70-chaperoned Ova-BiP by DC2.4 and Raw309 
 
(A) Incubation of dendritic cells or macrophages with peptide complexed to Hsp70 results in its 
processing and cross-presentation, whereas free peptide is not efficiently cross-presented at respective 
concentrations. (B) Fractions corresponding to those applied in A but without Hsp70 were tested for 
cross-presentable material. 
 
 
 
 
 
A B
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IV.2.2 Receptor mediated endocytosis is responsible for uptake 
 and cross-presentation of Hsp70-chaperoned peptide 
 The described cross-presentation of Hsp70-chaperoned Ova-BiP is efficient 
enough to be certain that it is due to receptor-mediated endocytosis. Additionally, it 
has been made sure that there is no free peptide present in the Hsp70/Ova-BiP 
preparations. However, in theory, peptide alone is also competent to be cross-presented 
by APCs if its concentration is high enough, and Hsp70/Ova-BiP could additionally be 
taken up by unspecific mechanisms. In order to completely rule out the participation of 
any kind of unspecific uptake of “bulk material”, an assay was developed that allows 
the initial association of Hsp70/Ova-BiP to the surface of the antigen presenting cell 
on ice, where no endocytotic activity can take place. Unbound material is then washed 
away and cells are warmed to physiologic temperature where they can take up 
receptor-bound material. Under these conditions, there is no cross-presentation of 
protein/peptide taken up by unspecific mechanisms such as macropinocytosis, and 
only Hsp70-chaperoned peptide is cross-presented (Figure 15).   
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Figure 15: Uptake and cross-presentation of Hsp70/Ova-BiP after association on ice. 
 
DC2.4 dendritic cells or Raw309 macrophages cells were incubated with indicated amounts of peptide, 
either complexed to Hsp70 or free in solution for 20 min on ice, followed by extensive washing before 
warming to 37 °C and incubation with B3Z T-cell hybrids. Hsp70-chaperoned peptide was efficiently 
cross-presented while no cross-presentation above background was detectable for administered free 
peptide. 
 
 
 These results provide a direct link between the previously shown specific 
binding of Hsp70 to the surface of antigen presenting cells and the capability of 
Hsp70-peptide complexes to elicit potent immune responses against the peptide 
chaperoned by them. Not only does Hsp70 “chaperone” the peptide to antigen 
presenting cells, but its binding to specific receptors on the surface of these cells leads 
to uptake, processing and cross-presentation of the peptides at concentrations not 
sufficient for free peptide to be cross-presented. Given these results and in 
dendritic cells macrophages 
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combination with the previous data, which showed a clear interaction of Hsp70 with 
the surface of antigen presenting cells both through its ATPase- and substrate-binding 
domain, it was know possible to address the question which of the determined 
interactions is the one responsible for the cross-presenting capabilities of the heat 
shock protein.  
 
IV.2.3 Analysis of the domains of Hsp70 necessary for cross-
 presentation 
 In order to analyze the cross-presenting capabilities of the individual Hsp70 
domains, two separate strategies were chosen. As the N-terminal domain showed 
nucleotide-dependent binding to the surface of antigen presenting cells, it was first 
addressed as a candidate for mediating the interaction responsible for the cross-
presenting potential of Hsp70. Since purified N70 lacks the substrate binding domain 
and thus cannot be loaded with peptide, an alternative strategy was chosen. Previously 
published data had shown successful immunization of mice with fusions between 
Hsp70 and substrate protein (Suzue et al., 1997), albeit the chaperone used for these 
studies was not of mammalian but of mycobacterial origin and is therefore only 
remotely related to the in vivo situation. Members of the same group later mapped the 
minimal portion of the Hsp70 molecule necessary to generate a CTL response against 
the polypeptide fused to it to the amino acids 161-370, which are located in the amino 
terminal ATPase domain (Huang et al., 2000). However, since one half of the ATP-
binding domain cannot be sufficient to retain chaperone activity, the authors conclude 
that the ability of their fusion proteins to elicit CD8+ T cells does not depend on the 
HSP moieties’ chaperone properties. 
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 In order to examine whether an interaction of such fusion proteins with the 
immune system takes place on the cellular level, similar fusions between murine 
Hsp70 or murine N70 (aa 161-370) and an ovalbumin domain containing the 
SIINFEKL epitope (OVA) were cloned and purified from E.coli. The fusion proteins 
were then incubated with DC2.4 and B3Z cells as described for the Hsp70/Ova-BiP 
complexes. While application of the Hsp70-OVA fusion resulted in some cross-
presentation of the SIINFEKL peptide, albeit considerably weaker than achieved 
through generated Hsp70/Ova-BiP complexes, the N70-OVA fusion did not exhibit 
any cross-presenting capability at all (Figure 16).  
 
 
 
Figure 16: Cross-presentation of SIINFEKL derived from fusion proteins. 
 
DC2.4. cells were capable of cross-presenting SIINFEKL derived from the Hsp70-OVA fusion at high 
concentrations, while no cross-presentation is detectable from the N70-Ova fusion. 
 
  
 These results indicate that the N-terminal domain alone is not responsible for 
the high efficiency of cross-presentation conferred by the full-length Hsp70 molecule. 
In order to analyze whether the C-terminal, substrate binding domain (SBD) might be 
sufficient to cross-present chaperoned peptides, the SBD of human Hsp70 was purified 
Results 80 
 
from E.coli as described for the full-length molecule. Isolated substrate binding 
domain (C70) bound Ova-BiP hybrid peptide in vitro, with binding kinetics that are 
much slower than those of the full-length molecule and a calculated K(d) of 730nM for 
FITC-labeled Ova-BiP (Figure 17a and b). 
 
 
 
 
Figure 17: The substrate binding domain is competent of chaperoning complexed 
peptide to the cross-presentation pathway of dendritic cells. 
 
(A) Binding curve of FITC-labeled Ova-BiP to C70 as measured by fluorescence anisotropy. (B) binding 
kinetics of C70 as compared with Hsp70. (C) highly efficient cross-presentation of C70-chaperoned 
peptide. 
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 As shown in Figure 17C, the isolated substrate binding domain of Hsp70 
efficiently chaperoned bound Ova-BiP to the cross-presentation pathway of dendritic 
cells. Given the roughly double dissociation constant of C70/Ova-BiP as compared to 
Hsp70/Ova-BiP, and taking into consideration that in the case of Hsp70, 20 % of the 
molecules are loaded with peptide, one could estimate that approximately 10 % of the 
C70 molecules employed for the cross-presentation studies are loaded with hybrid 
peptide. This would imply cross-presentation efficiencies of C70 which are roughly 
two-fold higher that those of the full-length Hsp70. This suggests strongly that the 
Hsp70 substrate binding domain is not only sufficient to bind and stabilize the peptide, 
but also to be the principal interaction partner of a cross-presentation-competent 
uptake receptor. 
 As for the full-length molecule, it was possible to discriminate between a 
possible situation in which C70 merely binds and stabilizes Ova-BiP and a specific, 
RME-induced cross-presentation process by experimentally separating the binding of 
C70/Ova-BiP complexes to the surface of dendritic cells from the uptake and 
processing steps. 
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Figure 18: Uptake and cross-presentation of C70/Ova-BiP after association on ice. 
 
 
 In such an experimental setup, the carboxy-terminal substrate binding domain 
of Hsp70 mediated highly efficient cross-presentation of the chaperoned peptide 
(Figure 18). This data provides a direct link between the observed cell-surface 
interaction of the SBD with the chaperone’s cross-presentation capability and clearly 
proves that this domain alone is necessary and sufficient for the molecules cross-
presenting capability. 
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IV.3 Analysis of cellular compartments involved in uptake of 
 the Hsp70/peptide complex 
 In order to obtain a more complete picture of the cross-presentation pathway 
taken by peptide-loaded Hsp70, an attempt was made to identify the cellular 
compartments involved in uptake and processing of the complex. For this purpose, an 
experimental system was developed which allows selective down-regulation of 
individual components of the cellular endocytic machinery. Dominant-negative 
mutants of four different small GTPases (DynI, Rab5, Rab7, and ARF6) as well as 
some constitutively active variants were utilized to specifically interfere with key steps 
of the endocytic process. Since the transfection efficiencies of dendritic cells or 
macrophages are too low to achieve a clear effect on the cross-presentation capabilities 
of a total cell population, a co-transfection approach was chosen to make sure that only 
cells expressing the respective mutant protein are being evaluated. For this purpose, 
Raw 264.7 macrophages, which were previously shown in this study to specifically 
interact with Hsp70/Ova-BiP complexes but lack the H-2K(b) molecule necessary for 
detection of cross-presentation by the B3Z system, were transiently transfected with an 
expression vector for k(b), thus gaining the ability to cross-present SIINFEKL peptide 
derived from Hsp70/Ova-BiP to B3Z cells (Figure 19A). For down-regulation of 
respective small GTPases, the macrophages were co-transfected with a mixture of 
k(b)-encoding and mutant-encoding plasmids in a ratio of 1:3, thus statistically 
ensuring that only such cells express the H-2k(b) molecule which also express the 
dominant negative mutant. Since the B3Z system as well as the 25D1.16 antibody 
solely recognize cells cross-presenting SIINFEKL on surface k(b) molecules, virtually 
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the entire analyzed cell population in this experimental setup carries the co-transfected 
plasmid.   
 Dynamin I (as well as Dynamin II) is a marker of early endocytotic steps where 
it is mainly involved in the pinching off of clathrin-coated pits. Many receptor-
mediated uptake processes are known to be dependent on this molecule, although some 
lipid-raft mediated pathways as well as macropinocytosis and phagocytosis have been 
shown to be independent of Dynamin. The dominant negative Dyn I K44A mutant is 
defective in its GTPase cycle and is known to cause a total inhibition of clathrin 
dynamics, while permitting receptor-mediated endocytosis by other means ((Boll et al., 
2004; Damke et al., 1994).  
 In order to correctly interpret the effect of Dyn I K44A expression in Raw 
264.7 macrophages on the cross-presentation of Hsp70 chaperoned peptide, it was 
crucial to determine whether the dominant negative Dynamin mutant has an impact on 
the expression level of the k(b) molecule itself. Since the available antibody against 
H2-k(b) is not sensitive enough to register changes in the expression level of the 
molecules, an approach was chosen which allows the employment of the highly 
sensitive B3Z system for this purpose. It is known that empty MHC molecules on the 
cell surface can be stabilized and become receptive for exogenously administered 
SIINFEKL peptide through cross-linking with paraformaldehyde (Rock et al., 1992). 
K(b) molecules loaded in such a manner can then be directly quantified by measuring 
B3Z response. In this as well as all following experiments, quantification of loaded 
K(b) molecules was performed by measuring B3Z response rather than employing the 
25D1.15 antibody, as the antibody staining was not sensitive enough to register 
changes in expression/cross-presentation levels.  
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Figure 19: Effect of DynIK44A on cross-presentation of Hsp70/Ova-BiP 
 
24h post transfection, Raw 264.7 macrophages were harvested and analyzed for K(b) expression and 
cross-presentation of Hsp70/Ova-BiP. (A) Macrophages cross-present SIINFEKL derived from 
Hsp70/Ova-BiP to B3Z when transfected with H-2k(b). (B) Raw 264.7 co-transfected with K(b) and Dyn I 
K44A express only ~30 % of the MHC class I molecules as compared with mock transfected. (C) Cross-
presentation of Hsp70/Ova-BiP by Dyn I K44A transfected cells is reduced to a similar amount as the 
level of k(b) molecules. 
 
   
 The expression of the dominant negative Dynamin I mutant resulted in 
significant decrease of H-2k(b) surface molecules (Figure 19B). Such an effect can 
possibly be explained by the fact that fluid phase uptake is known to increase upon 
RME inhibition. This down-regulation of MHC class I molecules to 34 % must be 
considered when quantifying the effect of the dominant negative mutant on Hsp70 
mediated cross-presentation. 
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 To access the role of clathrin-mediated endocytosis on the cross-presentation of 
Hsp70-chaperoned peptides, co-transfected macrophages were incubated with 
Hsp70/peptide complexes before quantifying cross-presentation as described in 
materials and methods. The cross-presentation of Hsp70-bound Ova-BiP was 
determined to be 48 % (data from three independent experiments) as compared with 
the cross-presentation of the complex by cells transfected with empty vector. Taking 
into account that the quantification of k(b) molecules had revealed a decrease of MHC 
class I molecules (34 % as compared to mock-transfected) on the surface of co-
transfected cells, it can be assumed that the observed reduction of cross-presentation is 
due to the lack of surface k(b) molecules and not to an interference in cross-
presentation pathways. This would imply that Dynamin I does not play a relevant role 
in the cross-presentation of Hsp70-chaperoned peptide. In agreement with this 
observation, microscopic analysis of the uptake pathway taken by Hsp70/Ova-BiP 
complexes revealed that the complexes are localized in transferrin-negative early 
endosomal structures shortly after uptake (data not shown).  
 The described approach was used to analyze the effects of other small GTPase 
mutants on MHC level and cross-presentation of Hsp70/Ova-BiP. Rab 5 was chosen as 
a marker of early endosomes and its mutants Rab5 S34N (dominant negative) and Rab 
Q79L (constitutively active) were co-transfected with H-2k(b) as described for Dyn I. 
Rab7 is a marker of late endosomes and lysosomes, and Rab7 Q67L is a dominant 
negative form of the protein. 
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 As shown in Figure 20A, transfection of Raw 264.7 macrophages with the Rab 
5 and Rab 7 mutants resulted in an extremely high fluctuation of k(b) expression under 
identical experimental conditions. In average, both Rab 5 mutants had little effect on 
MHC surface level, while the Rab 7 mutant resulted in elevated k(b) expression. This 
stabilization of MHC molecules could be due to inhibited lysosomal degradation. 
Accordingly, cross-presentation in the co-transfected cells was differentially affected 
by the mutant GTPases. While Rab 5 seems to result in a general decrease of Hsp70-
mediated cross-presentation of Ova-BiP, Rab 7 left the cells relatively unaffected.  
 
Figure 20: Effect of Rab 5 and Rab 7 on MHC class I level and cross-presentation 
Raw 264.7  
on Co-transfection of Dyn I K44A and H2-k(b) resulted in….. 
 
 
 
 
 
 
Figure 20: Effect of Rab5 and Rab7 mutants on MHC level and cross-presentation. 
(A) k(b) levels vary dramatically in cells co-transfected with Rab5 or Rab7 mutants as compared with 
mock transfected. Grey shades represent individual experiments. (B) Cross-presentation of Hsp70/Ova-
BiP cells transfected with Rab 5 and Rab 7 mutants.  
 
  
 Confocal studies with fluorescently labeled Hsp70 and Ova-BiP revealed a co-
localization of the complex in a Rab5 positive compartment within minutes after 
uptake, while only unloaded Hsp70 could be detected in lysosomal structures (data not 
shown).  
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 Initial experiments were also performed with mutant forms of the ADP 
ribosylation factor 6 (ARF 6). ARF6 is a small GTP-binding protein which plays a role 
in membrane recycling, phagocytosis, and cortical actin organization. It has been 
shown to participate in the recycling of MHC class I molecules, regulating a branch of 
dynamic tubular intermediates used by major histocompatibility class I molecules to 
traffic through vesicles between endosomes and the plasma membrane (Massol et al., 
2005), and is thought to play an important role in targeting recycling endosomes to the 
plasma membrane (D'Souza-Schorey et al., 1998). It has also been shown to participate 
in macrophage phagocytosis, as T27N, a dominant negative form of the ADP 
ribosylation factor 6, has been shown to inhibit phagocytosis via receptors for the Fc 
portion of immunoglobulins (FcR) (Niedergang et al., 2003).  
 
 
 
Figure 21: Effect of ARF6  mutants on MHC level and cross-presentation. 
(A) k(b) levels are reduced to 50 % in macrophages transfected with ARF6 mutants as compared to 
mock transfected cells. (B) Cross-presentation of Hsp70/Ova-BiP cells transfected with dominant 
negative ARF6 mutants. 
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 As expected, transfection of Raw 264.7 macrophages with the dominant 
negative mutants ARF6 Q67L and ARF6 T27N resulted in a strong decrease of co-
expressed k(b) surface level (Figure 21A). Cross-presentation of Hsp70-bound Ova-
BiP was not affected stronger than k(b) levels (Figure 21B), suggesting a cross-
presentation pathway independent of ARF6. Further experiments need to be performed 
to exclude a role of ARF6, and with it recycling endosomes, in Hsp70-mediated cross-
presentation, but the data collected until now indicates a clathrin-independent receptor-
mediated endocytosis of Hsp70-peptide complexes, followed by a participation of 
Rab5 positive early endosomes. Thus it appears that a participation of late endosomes, 
lysosomes or recycling endosomes can possibly be ruled out.  
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V DISCUSSION 
V.1 Interaction of Hsp70 with the surface of antigen 
 presenting cells 
 Heat shock proteins have been described as potent tumor vaccines and are 
currently being deployed in clinical trials. They were identified as tumor-specific 
antigens, and mice immunized with HSPs purified from a tumor are protected from a 
subsequent challenge with the tumor of origin.  The specificity of the immune response 
triggered by HSPs was ascribed to the peptides bound by them. As a direct 
consequence of the role of heat shock proteins as chaperones, they are thought to 
associate with a wide spectrum of peptides that reflects the entire antigenic repertoire 
of a cell.  
 Hsp70-peptide complexes have been shown to be released from cells dying 
from a number of pathological conditions, and the terminal stages of necrosis may also 
favor stable antigen binding by Hsp70, as intracellular ATP levels decline and peptides 
become locked onto the ADP-associated Hsp70 molecule during necrotic cell death 
(Calderwood et al., 2005b). 
 The first event in the interaction of extracellular Hsp70 with the immune 
system is the binding to the surface of professional antigen presenting cells (pAPCs). 
This binding event was characterized in the current study. For this purpose, 
recombinant human Hsp70 as well as its amino-terminal ATPase domain (N70) and 
carboxy-terminal substrate binding domain (C70) were purified and fluorescently 
labeled, with an emphasis on retaining functionality. A variety of cell lines were tested 
for their ability to bind Hsp70 and N70. It could be shown that the binding event is 
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specific for cells of the immune system (macrophages and dendritic cells), while non-
immune cells such as COS-7 and CHO did not show surface staining. This selective 
binding clearly supports the concept that APCs express one or more receptor 
molecules on their surface which are not expressed by other cells. 
 
 Further analysis of the binding behavior of Hsp70 to APCs revealed that the 
association of the chaperone with cell membranes is dependent on the molecule’s 
conformation. Hsp70 interacts with the putative receptors only in its substrate-bound, 
ADP-form, while the open conformation shows little or no surface staining. This 
phenomenon excludes the possibility that the interaction between Hsp70 and its 
receptor(s) is mediated by the chaperone-properties of the molecule, in a setting in 
which the receptor(s) would mimic a substrate of Hsp70 and the chaperone would bind 
this substrate in its peptide binding pocket. Physiologically, a preference of Hsp70-
receptors for the closed conformation of the molecule would ensure uptake only of 
substrate-loaded chaperone and not empty, “useless” molecules, thus enhancing the 
specificity of the immune response. Accordingly, immunization with in-vitro 
generated or purified HSP-peptide-complexes is known to be effective only when 
peptide is carried by the chaperone and not when the two are administered separately. 
On the molecular level, it is plausible that a receptor is able to distinguish between the 
two forms of Hsp70, as the molecule experiences a considerable conformational 
change upon substrate binding and ATP hydrolysis. 
  
 A number of cell surface molecules have been proposed as receptors for Hsp70, 
the most prominent ones being CD91 and CD40. The function of these molecules as 
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Hsp70 receptors was critically evaluated in the present study. In the case of CD40, 
ANA-1 macrophages were treated with lipopolysaccharide (LPS) and analyzed for 
Hsp70 binding. While LPS treatment resulted in a significant increase in CD40 
expression, binding of the chaperone was strongly reduced upon treatment with the 
endotoxin. This implies that while there is no causal connection between Hsp70 
binding and CD40 expression, there is an effect of LPS stimulation on the expression 
of the Hsp70 receptor(s). LPS stimulation of macrophages ultimately results in the 
activation of gene transcription, leading to a wide variety of rearrangements in the cell. 
It can be assumed that the expression of Hsp70 receptors is also affected by these 
rearrangements. Additionally, seems plausible that the chaperone interacts only with 
non-activated antigen presenting cells, as it itself has been shown to provide an 
activation signal to the innate immune system.  
 As the previously described interaction between Hsp70 and CD40 had been 
mapped to the aminoterminal domain of the chaperone (Becker et al., 2002), binding 
experiments were also carried out with the isolated NBD. Human embryonic kidney 
cells (HEK), transfected with a highly expressed CD40 construct, showed no increase 
of N70 binding as compared with mock transfected cells. This further underlined the 
concept that CD40, if at all, is not the sole receptor for Hsp70 binding.  
  
 In the case of CD91, we were able to exclude this molecule as a receptor for 
Hsp70. Binding of Hsp70 to the surface of macrophages was entirely independent of 
CD91 expression, as a macrophage cell line which does not express the molecule (Raw 
309) showed clear surface staining with Hsp70. The same cell line could also be 
shown to readily cross-present Hsp70-bound peptide, a property clearly dependent on 
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the presence of a receptor for Hsp70. Additionally, the group of Felix Wieland in 
Heidelberg could show that a cell line stably transfected with CD91 (CHO-CD91) did 
not show any surface binding of the chaperone. The CD91 molecule expressed by 
these cells was shown to be functional via the endotoxin A assay. In accordance, LPS-
stimulated Raw 264.7 macrophages, like ANA-1 macrophages, lost their ability to bind 
Hsp70, while surface levels of CD91 showed no alteration.  
 CD91 has been described as a receptor not only for Hsp70, but also for the 
chaperones Hsp90, calreticulin and gp96 (Basu et al., 2001). It is a large 
transmembrane protein also known by the names of LRP (LDL-receptor related 
protein), α2-macroglobulin-receptor and ApoE-receptor. It belongs to the family of 
scavenger receptors and as such binds a large variety of different substrates. It is 
feasible that a molecule with such a large variety of binding partners would also 
interact with Hsp70 under certain experimental conditions, but the specificity of 
interaction as described in this study could not be provided by such a promiscuous 
receptor.  
 
 Based on the observation that Hsp70 binds to the surface of antigen presenting 
cells in a conformation-dependent manner, the question was addressed which part(s) of 
the molecule contribute to these interactions. The aminoterminal ATPase domain 
displayed a binding behavior similar to that of the full-length molecule, demonstrating 
surface staining only in its ADP form. Interestingly, N70 displayed a punctuate 
binding pattern on the APC membrane, in contrast to the homogenous staining 
observed for the complete molecule. The substrate binding domain of Hsp70, C70, was 
also assayed for surface binding and revealed a punctuate pattern similar to that of 
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N70. This was the first indication that Hsp70 possibly possesses multiple interaction 
partners on the plasma membrane of APCs, and different moieties of the molecules 
interact with individual partners. This would be in agreement with the multiple 
functions that have been ascribed to it as an “immuno-chaperone”. 
 Further evidence for the existence of multiple cell-surface receptors for Hsp70 
was gained by competition experiments. The individual domains were examined for 
their capability to compete with each other for binding of the macrophage membrane. 
As expected for receptor-mediated interactions, the binding of labeled full length 
Hsp70 molecules could be fully out-competed by addition of a 20-fold excess of 
unlabeled Hsp70. In a similar manner, unlabeled N70 competed with N70 and C70 
competed with C70, verifying the specificity of interaction with cell-surface receptors. 
In contrast, the individual domains were not able to fully compete the binding of the 
full-length molecule, but rather reduced the homogenous staining to a punctuate 
pattern. Only a combination of both domains could fully interfere with the binding of 
Hsp70 to the macrophage membrane. Based on these observations, it becomes clear 
that at least two different receptors are responsible for binding of Hsp70 to the cell 
membrane, one of them interacting with the nucleotide binding domain and the other 
with the substrate binding domain of the chaperone. 
 Further analysis of the differential binding behavior of the individual domains 
was performed by our collaborators in the lab of Felix Wieland. N70 and C70 were 
labeled with different fluorescent dyes and incubated with Raw 264.7 macrophages. 
Confocal microscopy revealed heterogeneous staining with little overlap between the 
two domains, suggesting the binding of N70 and C70 to different micro-domains of the 
cell membrane.  
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 This phenomenon was accessed biochemically through separation of 
macrophage membranes into raft and non-raft fractions after incubation of cells with 
biotinylated Hsp70, N70 or C70. The fractions were then separated by SDS-PAGE and 
subjected to western blot analysis. HRP-tagged Cholera toxin was used as a marker of 
lipid rafts, as it interacts specifically with the raft glycolipid GM 1. While Hsp70 and 
C70 was detectable both in raft and in non-raft fractions, N70 could only be found 
outside of lipid rafts, further underlining the concept of differential binding sites for 
the individual domains of Hsp70.  
 
V.2 Cross-presentation of Hsp70-peptide complexes 
 The interaction of Hsp70 with antigen presenting cells results in stimulation of 
both innate and adaptive immune mechanisms. The activation of the adaptive immune 
system against peptides carried by Hsp70 is now understood to the extent that the 
complexes are taken up by receptor-mediated endocytosis (RME) and the peptides are 
processed (if necessary) and cross-presented on MHC class I molecules.  
 In this study, an in vitro system was established which allowed loading of 
Hsp70 with antigenic peptide and detecting the cross-presentation of the processed 
peptide in cultured dendritic cells and macrophages. Experiments performed with this 
system revealed that both dendritic cells and macrophages were capable of cross-
presenting peptide chaperoned by Hsp70, and this cross-presentation was highly 
efficient at concentrations at which free peptide was not cross-presented.  
 The question was addressed whether a direct connection exists between the 
described cell surface interaction of Hsp70 and the cross-presentation of chaperoned 
peptide. An assay allowing uptake only of membrane-bound Hsp70-peptide complexes 
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was developed and revealed a clear correlation between the two processes. The binding 
of Hsp70 to its cell-surface receptors clearly results in the cross-presentation of peptide 
bound by it on the APCs’ MHC class I molecules. Hsp70 thus does not merely act as a 
chaperone of peptides derived from dying cells, possibly protecting them from 
premature degradation in the blood stream, but indeed mediates the uptake of these 
peptides by cells capable of cross-presentation. We assumed that at least one of the 
interactions between the chaperone and the APC surface described in the previous 
section contributes to its cross-presentation capabilities. As the amino-terminal 
nucleotide binding domain cannot bind peptides, a fusion protein consisting of the 
NBD and a polypeptide containing antigenic peptide was employed. Incubation of 
antigen presenting cells with this fusion protein did not result in cross-presentation of 
the peptide, suggesting that the interaction between N70 and the APC surface is not the 
one responsible for Hsp70’s cross-presenting competency. 
 The substrate-binding domain of Hsp70 was purified and shown to be 
competent for loading with antigenic peptide in vitro. Cross-presentation experiments 
performed with C70-peptide complexes revealed a pronounced ability of the SBD to 
chaperone peptides onto the cross-presentation pathway of antigen presenting cells. As 
for the full-length molecule, this cross-presentation ability could be linked to the 
described binding of the C-terminal domain to the surface of antigen presenting cells.  
 The conclusion that C70 alone is the principle cross-presenting domain of the 
Hsp70 molecule is a key step in the understanding of Hsp70-mediated cross-
presentation. It could be hypothesized that the second interaction described in this 
study, that of N70 with differential microdomains on the APC membrane, results in the 
previously mentioned activation of innate immune mechanisms. Experiments 
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addressing this possibility are currently being carried out. Such a situation would allow 
a separation between the two main consequences of Hsp70 treatment, namely general 
immune stimulation and antigen-specific responses, thus facilitating exact dosage of 
each compound in clinical application. C70 is easy to purify and readily interacts with 
antigenic peptide, and as such could possibly be useful for immunization with 
complexes generated in vitro. The binding mechanism is separated from ATP binding 
and cleavage, which could possibly result in higher stability of chaperone-peptide 
complexes in vivo. It should become useful as an interaction partner for future screens 
which will be necessary to identify an uptake receptor for Hsp70/peptide complexes. 
 
V.3 Uptake pathway of Hsp70/peptide complexes 
 In order to fully understand the mechanism by which Hsp70 chaperones 
peptides onto the cross-presentation pathway of antigen-presenting cells, it was 
necessary to investigate the pathway taken by the complexes within the cross-
presenting cell.  
 Several independent models for antigen cross-presentation are currently being 
discussed, the general consensus being that the nature of the antigen defines which of 
the pathways is taken within the antigen presenting cell. Three main possibilities have 
been described for the fate of endocytosed antigens determined for cross-presentation: 
the “endosome-to-cytosol” pathway, the “recycling endosome” model as well as the 
“ER-phagosome model”. 
 In this study, two parallel approaches were chosen to gain understanding of the 
cellular compartments involved in Hsp70-mediated cross-presentation. Our laboratory 
employed dominant-negative mutants of small GTPases in order to specifically 
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interfere with endocytic processes and monitor the functional consequences of such 
interferences on the efficiency of cross-presentation. In parallel, our collaborators at 
the BZH in Heidelberg used fluorescently labeled Hsp70 and peptide to 
microscopically track the uptake of the complexes in cells capable of cross-presenting 
Hsp70-peptide complexes.  
 The dominant negative mutants employed in the study allow the interference 
with specific endocytic processes, in contrast to the frequently applied chemical 
inhibitors which have multiple, vaguely defined effects. A co-transfection approach 
was used which enabled the measurement of antigen cross-presentation with the B3Z 
cell line, allowing highly sensitive detection of MHC class I peptide presentation.  
 Unfortunately, the high sensitivity of the assay also resulted in a considerable 
fluctuation of the collected data, giving stable results only for one of the employed 
mutants, namely Dynamin I. 
 
 Interference with the formation of clathrin-coated pits by down-regulation of 
DynI activity resulted in a reduced cell-surface expression of MHC class I molecules. 
This can possibly be explained by the fact that inhibition of clathrin-coat formation 
initially leads to an increase of fluid phase uptake.   
  Hsp70-mediated cross-presentation, on the other hand, was unaffected by 
dynamin inhibition, supporting a clathrin-independent uptake pathway for the 
chaperone. Data from confocal microscopy confirmed this finding, showing an early 
localization of labeled Hsp70/Ova-BiP complexes in transferrin-negative 
compartments. Transferrin is a typical marker of clathrin-coated pits. Clathrin-
independent uptake has been described for phagocytic mechanisms carried out by 
Discussion 99 
 
macrophages and dendritic cells, usually participating in the endocytosis of pathogens 
or, in experimental setups, latex beads. The increasingly popular model of ER-
mediated phagocytosis describes a direct fusion of ER- and plasma-membrane 
resulting in phagocytosis (Desjardins and Griffiths, 2003; Gagnon et al., 2002)  and, in 
some cases, in cross-presentation of the internalized material (Guermonprez et al., 
2003; Houde et al., 2003).  
 
 The next endocytic step taken by Hsp70-peptide complexes was investigated by 
analyzing the role of Rab 5 in their uptake and cross-presentation. Rab 5 is a marker of 
early endosomes and plays a central role in membrane fusion (Mohrmann and van der 
Sluijs, 1999). It has also been described to be localized in phagosomes (Desjardins et 
al., 1994) where it is thought to promote the interaction of endosomes and phagosomes 
(kiss and run) (Duclos et al., 2000). 
 Confocal microscopy revealed an early co-localization (after 2 min at 19 °C) of 
Hsp70/Ova-BiP with Rab-5 molecules, indicating an accumulation of the chaperone-
peptide complexes in early endosomes or phagosomes, a process typical of receptor-
mediated endocytosis. Accordingly, data from the transfection of macrophages with 
GTPase mutants indicated an inhibitory effect of Rab 5 interference on Hsp70-
mediated cross-presentation. 
 The participation of ER structures in the cross-presentation pathway was 
examined through co-localization studies with PDI, an ER-resident enzyme. 
Interesstingly, an early localization of fully internalized Hsp70/Ova-BiP complexes in 
PDI-positive compartments could be shown. This could be a first indication of an 
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interaction of ER-structures with endosomal vesicles in the proximity of the plasma 
membrane. 
 Inhibition of Rab 7, a lysosomal marker, had no effect on Hsp70-mediated 
cross-presentation. When analyzed microscopically, a co-localization with Lyso 
Tracker could only be shown for empty, unloaded Hsp70 molecules, possibly 
indicating a degradation of the chaperone after “antigen-delivery” to the cross-
presentation pathway of the antigen-presenting cell.  
 Similarly, preliminary experiments performed with mutated ARF6, a GTPase 
responsible for membrane fusion of recycling endosomes, showed no effect on the 
cross-presentation efficiency of Hsp-bound peptide, arguing against the so-called 
“recycling endosome” model.  
 A detailed understanding of the pathway of Hsp70-mediated cross-presentation 
will require further analysis. The employment of chemical inhibitors of endocytic 
processes would be one possibility to further underline the generated results. 
Additionally, APCs stably transfected with the available dominant negative mutants of 
small GTPases could possibly overcome the variability problem associated with 
transient transfection. 
 Based on the data at hand, a preliminary model can be proposed which resolves 
how Hsp70 delivers antigen to the cross-presentation pathway of APCs (Figure 22): 
Hsp70 is loaded with antigenic peptide in the cytosol of virally infected or tumor cells, 
from which it is released during necrotic cell death. A decrease of ATP concentration 
in the dying cell locks the chaperone in its ADP state and ensures tight substrate 
binding.  
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Figure 22: Model of Hsp70-mediated antigen cross-presentation 
 
(A) Release of Hsp70/peptide complexes during necrotic cell death. (B) Binding of Hsp70-peptide 
complexes to uptake receptors on the APC surface is mediated by the chaperone’s substrate binding 
domain. (C) Additionally, the nucleotide binding domain of Hsp70 can interact with the APC surface. (D) 
Internalized Hsp70/peptide complexes are transported into Rab 5 - positive endosomes, from which the 
antigenic peptides gain access to ER-like, cross-presentation-competent structures (E), where they are 
loaded on MHC class I molecules and presented on the cell surface. (F) Empty Hsp70 molecules are 
transported into lysosomes where they become degraded. 
 
 
 
 Peptide-loaded Hsp70 specifically interacts with a set of receptors on the 
surface of antigen presenting cells. Uptake of the chaperone, resulting in cross-
presentation of the delivered antigen, is mediated by the molecule’s carboxy-terminal 
substrate binding domain. Other interactions, including that of the aminoterminal 
domain of Hsp70, are not yet fully understood, but might result in stimulation of the 
antigen presenting cell.  
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 Receptor-mediated endocytosis of Hsp70/peptide complexes leads to a rapid 
uptake and accumulation in Rab 5 positive endosomal/phagosomal structures, from 
which the complexes gain access to MHC class I presentation competent, ER-like 
structures. While the bound peptide is loaded on MHC class I molecules and presented 
on the cell’s surface, empty Hsp70 molecules are transported into lysosomes where 
they are degraded.  
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VII APPENDIX 
VII.1 Abbreviations 
 
(p)APC  (professional) antigen presenting cell 
aa   amino acid 
ADP   adenosine 5’-diphosphate 
Amp   ampicillin 
APS   ammonium peroxodisulfate 
ATP   adenosine 5’-triphosphate 
BSA   bovine serum albumin 
C70   carboxy-terminal substrate binding domain 
CTL   cytotoxic T-lymphocyte 
CPRG   Chlorophenolred-β-D-galactopyroanoside 
DC   dendritic cell 
dn   dominant negative 
DMSO  dimethyl-sulfoxide 
Dyn I   Dynamin 1 
E. coli   Escherichia coli 
ER   endoplasmic reticulum 
ERAD   ER associated degradation 
FACS   fluorescence-activated cell sorting 
FITC   fluorescein isothiocyanate 
HRP   horse radish peroxidase 
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HSP   heat shock protein 
IPTG   isopropyl-β-D-1-thiogalactopyranoside 
LPS   lipopolysaccharide 
MΦ   macrophage 
MHC   major histocompatability complex 
N70   amino-terminal nucleotide binding domain of Hsp70 
NAC   nascent chain associated complex 
NBD   nucleotide binding domain 
OD   optical density 
PFA   paraformaldehyde 
PBS   phosphate buffered saline 
RAC   ribosome-associated complex 
RME   Receptor mediated endocytosis 
SBD   substrate binding domain 
S. cerevisiae  Saccharomyces cerevisiae 
TEMED  N,N,N’N-tetramethylethylendiamine 
TF   trigger factor 
TLC   thin layer chromatography 
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